{"generated":"2026-08-28T16:42:09Z","content_changed":"2026-08-28T15:15:36Z","count":296,"licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","note":"Trialacroniem -> artikelen op hartvaat.nl. Eerlijk afgeleid: alleen het acroniem dat een titel opent en aan een dubbele punt voorafgaat (bijv. 'FINEARTS-HF: ...'); artikelen zonder die vorm ontbreken hier, zoek ze via articles.json.","trials":[{"trial":"FINEARTS-HF","count":16,"first_published":"2024-10-24","last_published":"2025-08-01","articles":[{"url":"https://hartvaat.nl/2025/08/01/finearts-hf-finerenon-naar-frailteit-bij-hartfalen/","title":"FINEARTS-HF: finerenon naar frailteit bij hartfalen","published":"2025-08-01","doi":"10.1001/jamacardio.2025.1775","journal":"JAMA cardiology","significance":6},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-bij-hartfalen-met-verbeterde-ejectiefractie/","title":"FINEARTS-HF: finerenon bij hartfalen met verbeterde ejectiefractie","published":"2025-07-01","doi":"10.1001/jamacardio.2025.1101","journal":"JAMA cardiology","significance":7},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-modus-van-overlijden-bij-hfmref-hfpef/","title":"FINEARTS-HF: modus van overlijden bij HFmrEF/HFpEF","published":"2025-07-01","doi":"10.1001/jamacardio.2025.0860","journal":"JAMA cardiology","significance":5},{"url":"https://hartvaat.nl/2025/07/01/finearts-hf-finerenon-en-atriumfibrilleren-bij-hartfalen/","title":"FINEARTS-HF: finerenon en atriumfibrilleren bij hartfalen","published":"2025-07-01","doi":"10.1001/jamacardio.2025.0848","journal":"JAMA cardiology","significance":6},{"url":"https://hartvaat.nl/2025/06/01/finearts-hf-finerenon-en-predict-hfpef-risicoscore/","title":"FINEARTS-HF: finerenon en PREDICT-HFpEF risicoscore","published":"2025-06-01","doi":"10.1001/jamacardio.2025.0025","journal":"JAMA cardiology","significance":5},{"url":"https://hartvaat.nl/2025/02/01/finearts-hf-geschatte-langetermijnvoordelen-van-finerenon-bij-hartfalen/","title":"FINEARTS-HF: geschatte langetermijnvoordelen van finerenon bij hartfalen","published":"2025-02-01","doi":"10.1001/jamacardio.2024.3782","journal":"JAMA cardiology","significance":6},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-initiele-egfr-dip-met-finerenon-bij-hfpef-is-veilig/","title":"FINEARTS-HF: initiële eGFR-dip met finerenon bij HFpEF is veilig","published":"2025-01-21","doi":"10.1016/j.jacc.2024.11.020","journal":"Journal of the American College of Cardiology","significance":6},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-obesitas-bij-hfmref-hfpef/","title":"FINEARTS-HF: finerenon en obesitas bij HFmrEF/HFpEF","published":"2025-01-21","doi":"10.1016/j.jacc.2024.10.111","journal":"Journal of the American College of Cardiology","significance":6},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-kccq-bij-hfmref-hfpef/","title":"FINEARTS-HF: finerenon en KCCQ bij HFmrEF/HFpEF","published":"2025-01-21","doi":"10.1016/j.jacc.2024.09.023","journal":"Journal of the American College of Cardiology","significance":6},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-en-nieruitkomsten-bij-hfpef/","title":"FINEARTS-HF: finerenon en nieruitkomsten bij HFpEF","published":"2025-01-21","doi":"10.1016/j.jacc.2024.10.091","journal":"Journal of the American College of Cardiology","significance":6},{"url":"https://hartvaat.nl/2025/01/21/finearts-hf-finerenon-bij-recent-verslechterend-hartfalen/","title":"FINEARTS-HF: finerenon bij recent verslechterend hartfalen","published":"2025-01-21","doi":"10.1016/j.jacc.2024.09.004","journal":"Journal of the American College of Cardiology","significance":7},{"url":"https://hartvaat.nl/2025/01/14/finearts-hf-finerenon-met-en-zonder-sglt2-remmer-bij-hfpef/","title":"FINEARTS-HF: finerenon met en zonder SGLT2-remmer bij HFpEF","published":"2025-01-14","doi":"10.1161/CIRCULATIONAHA.124.072055","journal":"Circulation","significance":7},{"url":"https://hartvaat.nl/2025/01/07/finearts-hf-finerenon-effectief-over-het-hele-ef-spectrum-bij-hfmref-hfpef/","title":"FINEARTS-HF: finerenon effectief over het hele EF-spectrum bij HFmrEF/HFpEF","published":"2025-01-07","doi":"10.1161/CIRCULATIONAHA.124.072011","journal":"Circulation","significance":8},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-gelijk-effectief-bij-vrouwen-en-mannen-met-hfpef/","title":"FINEARTS-HF: finerenon gelijk effectief bij vrouwen en mannen met HFpEF","published":"2025-01-01","doi":"10.1001/jamacardio.2024.4613","journal":"JAMA cardiology","significance":6},{"url":"https://hartvaat.nl/2025/01/01/finearts-hf-finerenon-kalium-en-klinische-uitkomsten-bij-hfpef/","title":"FINEARTS-HF: finerenon, kalium en klinische uitkomsten bij HFpEF","published":"2025-01-01","doi":"10.1001/jamacardio.2024.4539","journal":"JAMA cardiology","significance":7},{"url":"https://hartvaat.nl/2024/10/24/finearts-hf-finerenon-bij-hfmref-hfpef-nejm/","title":"FINEARTS-HF: finerenon bij HFmrEF/HFpEF — NEJM","published":"2024-10-24","doi":"10.1056/NEJMoa2407107","journal":"The New England journal of medicine","significance":10}]},{"trial":"DELIVER","count":9,"first_published":"2022-09-22","last_published":"2024-03-01","articles":[{"url":"https://hartvaat.nl/2024/03/01/deliver-dapagliflozine-vermindert-plotse-hartdood-bij-verbeterde-ef/","title":"DELIVER: dapagliflozine vermindert plotse hartdood bij verbeterde EF","published":"2024-03-01","doi":"10.1001/jamacardio.2023.5318","journal":"JAMA cardiology","significance":7},{"url":"https://hartvaat.nl/2024/02/01/deliver-egfr-dip-na-dapagliflozine-bij-hfpef-is-veilig/","title":"DELIVER: eGFR-dip na dapagliflozine bij HFpEF is veilig","published":"2024-02-01","doi":"10.1001/jamacardio.2023.4664","journal":"JAMA cardiology","significance":6},{"url":"https://hartvaat.nl/2023/07/01/deliver-dapagliflozine-verbetert-individuele-kccq-componenten-bij-hfpef/","title":"DELIVER: dapagliflozine verbetert individuele KCCQ-componenten bij HFpEF","published":"2023-07-01","doi":"10.1001/jamacardio.2023.1342","journal":"JAMA cardiology","significance":6},{"url":"https://hartvaat.nl/2023/01/01/deliver-dapagliflozine-beschermt-ook-de-nieren-bij-hfpef/","title":"DELIVER: dapagliflozine beschermt ook de nieren bij HFpEF","published":"2023-01-01","doi":"10.1001/jamacardio.2022.4210","journal":"JAMA cardiology","significance":7},{"url":"https://hartvaat.nl/2022/12/01/deliver-snel-voordeel-van-dapagliflozine-bij-hfpef-binnen-weken-merkbaar/","title":"DELIVER: snel voordeel van dapagliflozine bij HFpEF — binnen weken merkbaar","published":"2022-12-01","doi":"10.1001/jamacardio.2022.3750","journal":"JAMA cardiology","significance":7},{"url":"https://hartvaat.nl/2022/11/01/deliver-dapagliflozine-effectief-bij-hfpef-ongeacht-atriumfibrilleren/","title":"DELIVER: dapagliflozine effectief bij HFpEF ongeacht atriumfibrilleren","published":"2022-11-01","doi":"10.1016/j.jacc.2022.08.718","journal":"Journal of the American College of Cardiology","significance":7},{"url":"https://hartvaat.nl/2022/10/18/deliver-dapagliflozine-effectief-ongeacht-frailteit-bij-hfpef/","title":"DELIVER: dapagliflozine effectief ongeacht frailteit bij HFpEF","published":"2022-10-18","doi":"10.1161/CIRCULATIONAHA.122.061754","journal":"Circulation","significance":8},{"url":"https://hartvaat.nl/2022/10/04/deliver-dapagliflozine-effectief-bij-recent-gehospitaliseerde-hfpef-patienten/","title":"DELIVER: dapagliflozine effectief bij recent gehospitaliseerde HFpEF-patiënten","published":"2022-10-04","doi":"10.1016/j.jacc.2022.07.021","journal":"Journal of the American College of Cardiology","significance":8},{"url":"https://hartvaat.nl/2022/09/22/deliver-dapagliflozine-effectief-bij-hfmref-en-hfpef/","title":"DELIVER: dapagliflozine effectief bij HFmrEF en HFpEF","published":"2022-09-22","doi":"10.1056/NEJMoa2206286","journal":"The New England journal of medicine","significance":10}]},{"trial":"SUMMIT","count":6,"first_published":"2025-01-30","last_published":"2025-09-09","articles":[{"url":"https://hartvaat.nl/2025/09/09/summit-tirzepatide-effect-bij-hfpef-met-en-zonder-diabetes/","title":"SUMMIT: tirzepatide-effect bij HFpEF met en zonder diabetes","published":"2025-09-09","doi":"10.1016/j.jacc.2025.06.058","journal":"Journal of the American College of Cardiology","significance":6},{"url":"https://hartvaat.nl/2025/07/29/summit-bmi-centrale-adipositas-en-gewichtsverlies-beinvloeden-tirzepatide-effect/","title":"SUMMIT: BMI, centrale adipositas en gewichtsverlies beïnvloeden tirzepatide-effect bij HFpEF","published":"2025-07-29","doi":"10.1016/j.jacc.2025.04.059","journal":"Journal of the American College of Cardiology","significance":6},{"url":"https://hartvaat.nl/2025/05/13/summit-tirzepatide-en-ckd-interactie-bij-hfpef-met-obesitas/","title":"SUMMIT: tirzepatide en CKD-interactie bij HFpEF met obesitas","published":"2025-05-13","doi":"10.1016/j.jacc.2025.03.009","journal":"Journal of the American College of Cardiology","significance":6},{"url":"https://hartvaat.nl/2025/03/11/summit-tirzepatide-en-klinisch-traject-bij-hfpef-met-obesitas-langetermijn/","title":"SUMMIT: tirzepatide en klinisch traject bij HFpEF met obesitas — langetermijn","published":"2025-03-11","doi":"10.1161/CIRCULATIONAHA.124.072679","journal":"Circulation","significance":7},{"url":"https://hartvaat.nl/2025/02/25/summit-tirzepatide-vermindert-lv-massa-en-paracardiaal-vetweefsel-bij-hfpef/","title":"SUMMIT: tirzepatide vermindert LV-massa en paracardiaal vetweefsel bij HFpEF","published":"2025-02-25","doi":"10.1016/j.jacc.2024.11.001","journal":"Journal of the American College of Cardiology","significance":7},{"url":"https://hartvaat.nl/2025/01/30/summit-tirzepatide-bij-hfpef-met-obesitas-nejm/","title":"SUMMIT: tirzepatide bij HFpEF met obesitas — NEJM","published":"2025-01-30","doi":"10.1056/NEJMoa2410027","journal":"The New England journal of medicine","significance":10}]},{"trial":"ADVOR","count":4,"first_published":"2022-09-29","last_published":"2023-10-01","articles":[{"url":"https://hartvaat.nl/2023/10/01/advor-nierfunctie-en-decongestie-met-acetazolamide/","title":"ADVOR: nierfunctie en decongestie met acetazolamide","published":"2023-10-01","doi":"10.1093/eurheartj/ehad557","journal":"European heart journal","significance":7},{"url":"https://hartvaat.nl/2023/06/09/advor-bicarbonaatwaarden-en-decongestie-effect-van-acetazolamide/","title":"ADVOR: bicarbonaatwaarden en decongestie-effect van acetazolamide","published":"2023-06-09","doi":"10.1093/eurheartj/ehad236","journal":"European heart journal","significance":6},{"url":"https://hartvaat.nl/2023/01/17/advor-acetazolamide-effectief-over-het-hele-ef-spectrum-bij-acuut-hartfalen/","title":"ADVOR: acetazolamide effectief over het hele EF-spectrum bij acuut hartfalen","published":"2023-01-17","doi":"10.1161/CIRCULATIONAHA.122.062486","journal":"Circulation","significance":7},{"url":"https://hartvaat.nl/2022/09/29/advor-acetazolamide-bij-acuut-gedecompenseerd-hartfalen-met-volumeoverbelasting/","title":"ADVOR: acetazolamide bij acuut gedecompenseerd hartfalen met volumeoverbelasting","published":"2022-09-29","doi":"10.1056/NEJMoa2203094","journal":"The New England journal of medicine","significance":10}]},{"trial":"ESPRIT","count":4,"first_published":"2025-10-28","last_published":"2026-01-06","articles":[{"url":"https://hartvaat.nl/2026/01/06/esprit-intensieve-bloeddrukcontrole-bij-fragiele-patienten-post-hoc-analyse/","title":"ESPRIT: intensieve bloeddrukcontrole bij fragiele patiënten — post-hoc analyse","published":"2026-01-06","doi":"10.1016/j.jacc.2025.08.092","journal":"Journal of the American College of Cardiology","significance":7},{"url":"https://hartvaat.nl/2025/10/28/esprit-bescheiden-effecten-van-intensieve-bloeddrukverlaging-op-kwaliteit-van-le/","title":"ESPRIT: bescheiden effecten van intensieve bloeddrukverlaging op kwaliteit van leven","published":"2025-10-28","doi":"10.1016/j.jacc.2025.06.010","journal":"Journal of the American College of Cardiology","significance":6},{"url":"https://hartvaat.nl/2025/10/28/esprit-intensieve-bloeddrukverlaging-en-retinale-microvasculatuur/","title":"ESPRIT: intensieve bloeddrukverlaging en retinale microvasculatuur","published":"2025-10-28","doi":"10.1016/j.jacc.2025.05.020","journal":"Journal of the American College of Cardiology","significance":5},{"url":"https://hartvaat.nl/2025/10/28/esprit-intensieve-bloeddrukcontrole-en-cva-preventie/","title":"ESPRIT: intensieve bloeddrukcontrole en CVA-preventie","published":"2025-10-28","doi":"10.1016/j.jacc.2025.07.055","journal":"Journal of the American College of Cardiology","significance":8}]},{"trial":"IRONMAN","count":4,"first_published":"2022-12-17","last_published":"2025-06-13","articles":[{"url":"https://hartvaat.nl/2025/06/13/ironman-leeftijdgestratificeerde-effecten-van-iv-ijzer-bij-hf/","title":"IRONMAN: leeftijdgestratificeerde effecten van IV-ijzer bij HF","published":"2025-06-13","doi":"10.1136/heartjnl-2024-324908","journal":"Heart (British Cardiac Society)","significance":6},{"url":"https://hartvaat.nl/2024/10/29/ironman-adjudicatie-van-hospitalisaties-en-sterfgevallen-heranalyse/","title":"IRONMAN: adjudicatie van hospitalisaties en sterfgevallen — heranalyse","published":"2024-10-29","doi":"10.1016/j.jacc.2024.08.052","journal":"Journal of the American College of Cardiology","significance":8},{"url":"https://hartvaat.nl/2024/04/21/ironman-ijzerdeficientiedefinities-en-klinische-respons-op-iv-ijzer-bij-hf/","title":"IRONMAN: ijzerdeficiëntiedefinities en klinische respons op IV-ijzer bij HF","published":"2024-04-21","doi":"10.1093/eurheartj/ehae086","journal":"European heart journal","significance":6},{"url":"https://hartvaat.nl/2022/12/17/ironman-intraveneus-ijzer-bij-hartfalen-met-ijzerdeficientie-lancet-rct/","title":"IRONMAN: intraveneus ijzer bij hartfalen met ijzerdeficiëntie — Lancet RCT","published":"2022-12-17","doi":"10.1016/S0140-6736(22)02083-9","journal":"Lancet (London, England)","significance":9}]},{"trial":"ISCHEMIA","count":4,"first_published":"2023-09-19","last_published":"2025-09-16","articles":[{"url":"https://hartvaat.nl/2025/09/16/ischemia-anginatrajecten-na-invasieve-versus-conservatieve-strategie/","title":"ISCHEMIA: anginatrajecten na invasieve versus conservatieve strategie","published":"2025-09-16","doi":"10.1016/j.jacc.2025.06.044","journal":"Journal of the American College of Cardiology","significance":7},{"url":"https://hartvaat.nl/2025/04/01/ischemia-invasief-versus-conservatief-bij-chronische-totale-occlusie/","title":"ISCHEMIA: invasief versus conservatief bij chronische totale occlusie","published":"2025-04-01","doi":"10.1016/j.jacc.2025.01.029","journal":"Journal of the American College of Cardiology","significance":7},{"url":"https://hartvaat.nl/2024/09/29/ischemia-atherosclerosekwantificering-en-cv-risico/","title":"ISCHEMIA: atherosclerosekwantificering en CV-risico","published":"2024-09-29","doi":"10.1093/eurheartj/ehae471","journal":"European heart journal","significance":7},{"url":"https://hartvaat.nl/2023/09/19/ischemia-impact-van-complete-revascularisatie-op-uitkomsten/","title":"ISCHEMIA: impact van complete revascularisatie op uitkomsten","published":"2023-09-19","doi":"10.1016/j.jacc.2023.06.015","journal":"Journal of the American College of Cardiology","significance":7}]},{"trial":"STRONG-HF","count":4,"first_published":"2022-12-03","last_published":"2025-06-01","articles":[{"url":"https://hartvaat.nl/2025/06/01/strong-hf-socio-economische-status-beinvloedt-gdmt-effect-niet/","title":"STRONG-HF: socio-economische status beïnvloedt GDMT-effect niet","published":"2025-06-01","doi":"10.1002/ehf2.15156","journal":"ESC heart failure","significance":6},{"url":"https://hartvaat.nl/2023/08/14/strong-hf-nt-probnp-geleide-intensieve-optitratie-na-acuut-hf/","title":"STRONG-HF: NT-proBNP-geleide intensieve optitratie na acuut HF","published":"2023-08-14","doi":"10.1093/eurheartj/ehad335","journal":"European heart journal","significance":7},{"url":"https://hartvaat.nl/2023/06/06/strong-hf-optitratie-effectief-over-het-hele-ef-spectrum-na-hf-opname/","title":"STRONG-HF: optitratie effectief over het hele EF-spectrum na HF-opname","published":"2023-06-06","doi":"10.1016/j.jacc.2023.03.426","journal":"Journal of the American College of Cardiology","significance":8},{"url":"https://hartvaat.nl/2022/12/03/strong-hf-snelle-optitratie-van-hartfalenmedicatie-na-ziekenhuis-is-veilig-en-ef/","title":"STRONG-HF: snelle optitratie van hartfalenmedicatie na ziekenhuis is veilig en effectief","published":"2022-12-03","doi":"10.1016/S0140-6736(22)02076-1","journal":"Lancet (London, England)","significance":10}]},{"trial":"ARTESIA","count":3,"first_published":"2024-01-11","last_published":"2025-12-01","articles":[{"url":"https://hartvaat.nl/2025/12/01/artesia-majeure-bloedingen-met-apixaban-versus-aspirine-subanalyse/","title":"ARTESIA: majeure bloedingen met apixaban versus aspirine — subanalyse","published":"2025-12-01","doi":"10.1001/jamacardio.2025.4151","journal":"JAMA cardiology","significance":6},{"url":"https://hartvaat.nl/2024/07/23/artesia-apixaban-versus-aspirine-naar-cha2ds2-vasc-bij-subclinisch-af/","title":"ARTESIA: apixaban versus aspirine naar CHA₂DS₂-VASc bij subclinisch AF","published":"2024-07-23","doi":"10.1016/j.jacc.2024.05.002","journal":"Journal of the American College of Cardiology","significance":7},{"url":"https://hartvaat.nl/2024/01/11/artesia-apixaban-bij-subclinisch-af-nejm/","title":"ARTESIA: apixaban bij subclinisch AF — NEJM","published":"2024-01-11","doi":"10.1056/NEJMoa2310234","journal":"The New England journal of medicine","significance":10}]},{"trial":"COMBINE AF","count":3,"first_published":"2023-06-06","last_published":"2025-08-12","articles":[{"url":"https://hartvaat.nl/2025/08/12/combine-af-overstap-naar-nieuwer-anticoagulans-versus-warfarine-bij-ouderen/","title":"COMBINE AF: overstap naar nieuwer anticoagulans versus warfarine bij ouderen","published":"2025-08-12","doi":"10.1016/j.jacc.2025.05.060","journal":"Journal of the American College of Cardiology","significance":6},{"url":"https://hartvaat.nl/2024/03/19/combine-af-noac-s-versus-warfarine-over-bmi-spectrum-bij-af/","title":"COMBINE AF: NOAC's versus warfarine over BMI-spectrum bij AF","published":"2024-03-19","doi":"10.1161/CIRCULATIONAHA.123.066279","journal":"Circulation","significance":7},{"url":"https://hartvaat.nl/2023/06/06/combine-af-doac-s-versus-warfarine-over-het-nierfunctiespectrum-ipd-meta-analyse/","title":"COMBINE AF: DOAC's versus warfarine over het nierfunctiespectrum — IPD meta-analyse","published":"2023-06-06","doi":"10.1161/CIRCULATIONAHA.122.062752","journal":"Circulation","significance":8}]},{"trial":"EAST-AFNET 4","count":3,"first_published":"2023-05-19","last_published":"2025-09-01","articles":[{"url":"https://hartvaat.nl/2025/09/01/east-afnet-4-diabetes-obesitas-en-vroege-ritmecontrole-bij-af/","title":"EAST-AFNET 4: diabetes, obesitas en vroege ritmecontrole bij AF","published":"2025-09-01","doi":"10.1001/jamacardio.2025.2374","journal":"JAMA cardiology","significance":6},{"url":"https://hartvaat.nl/2024/06/03/east-afnet-4-natriumkanaalblokkers-veilig-en-effectief-voor-langetermijn-ritmeco/","title":"EAST-AFNET 4: natriumkanaalblokkers veilig en effectief voor langetermijn ritmecontrole","published":"2024-06-03","doi":"10.1093/europace/euae121","journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","significance":7},{"url":"https://hartvaat.nl/2023/05/19/east-afnet-4-vroege-ritmecontrole-bij-af-is-kosteneffectief/","title":"EAST-AFNET 4: vroege ritmecontrole bij AF is kosteneffectief","published":"2023-05-19","doi":"10.1093/europace/euad051","journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","significance":7}]},{"trial":"FLOW","count":3,"first_published":"2024-07-11","last_published":"2025-03-24","articles":[{"url":"https://hartvaat.nl/2025/03/24/flow-semaglutide-cv-voordelen-naar-ckd-ernst-bij-diabetes/","title":"FLOW: semaglutide CV-voordelen naar CKD-ernst bij diabetes","published":"2025-03-24","doi":"10.1093/eurheartj/ehae613","journal":"European heart journal","significance":7},{"url":"https://hartvaat.nl/2024/10/22/flow-semaglutide-vermindert-hartfalen-bij-diabetes-en-ckd/","title":"FLOW: semaglutide vermindert hartfalen bij diabetes en CKD","published":"2024-10-22","doi":"10.1016/j.jacc.2024.08.004","journal":"Journal of the American College of Cardiology","significance":8},{"url":"https://hartvaat.nl/2024/07/11/flow-semaglutide-beschermt-nieren-bij-type-2-diabetes-en-ckd-nejm-gerelateerd/","title":"FLOW: semaglutide beschermt nieren bij type 2 diabetes en CKD — NEJM-gerelateerd","published":"2024-07-11","doi":"10.1056/NEJMoa2403347","journal":"The New England journal of medicine","significance":10}]},{"trial":"ILUMIEN IV","count":3,"first_published":"2023-10-19","last_published":"2024-11-14","articles":[{"url":"https://hartvaat.nl/2024/11/14/ilumien-iv-oct-predictoren-van-klinische-uitkomsten-na-stentimplantatie/","title":"ILUMIEN IV: OCT-predictoren van klinische uitkomsten na stentimplantatie","published":"2024-11-14","doi":"10.1093/eurheartj/ehae521","journal":"European heart journal","significance":6},{"url":"https://hartvaat.nl/2024/07/23/ilumien-iv-oct-geleide-pci-bij-complexe-laesies-subanalyse/","title":"ILUMIEN IV: OCT-geleide PCI bij complexe laesies — subanalyse","published":"2024-07-23","doi":"10.1016/j.jacc.2024.04.037","journal":"Journal of the American College of Cardiology","significance":6},{"url":"https://hartvaat.nl/2023/10/19/ilumien-iv-oct-geleide-versus-angiografie-geleide-pci-nejm/","title":"ILUMIEN IV: OCT-geleide versus angiografie-geleide PCI — NEJM","published":"2023-10-19","doi":"10.1056/NEJMoa2305861","journal":"The New England journal of medicine","significance":8}]},{"trial":"ORBITA-2","count":3,"first_published":"2023-12-21","last_published":"2026-01-27","articles":[{"url":"https://hartvaat.nl/2026/01/27/orbita-2-leeftijd-en-pci-effectiviteit-bij-stabiel-coronairlijden/","title":"ORBITA-2: leeftijd en PCI-effectiviteit bij stabiel coronairlijden","published":"2026-01-27","doi":"10.1016/j.jacc.2025.10.086","journal":"Journal of the American College of Cardiology","significance":6},{"url":"https://hartvaat.nl/2025/05/13/orbita-2-dobutamine-stress-echo-voorspelt-pci-effectiviteit/","title":"ORBITA-2: dobutamine-stress-echo voorspelt PCI-effectiviteit","published":"2025-05-13","doi":"10.1016/j.jacc.2025.02.034","journal":"Journal of the American College of Cardiology","significance":7},{"url":"https://hartvaat.nl/2023/12/21/orbita-2-pci-versus-placebo-bij-stabiele-angina-pectoris-nejm/","title":"ORBITA-2: PCI versus placebo bij stabiele angina pectoris — NEJM","published":"2023-12-21","doi":"10.1056/NEJMoa2310610","journal":"The New England journal of medicine","significance":10}]},{"trial":"PARADISE-MI","count":3,"first_published":"2022-10-04","last_published":"2024-03-05","articles":[{"url":"https://hartvaat.nl/2024/03/05/paradise-mi-sacubitril-valsartan-bij-stemi-versus-nstemi/","title":"PARADISE-MI: sacubitril/valsartan bij STEMI versus NSTEMI","published":"2024-03-05","doi":"10.1016/j.jacc.2024.01.002","journal":"Journal of the American College of Cardiology","significance":6},{"url":"https://hartvaat.nl/2022/12/06/paradise-mi-sacubitril-valsartan-vermindert-coronaire-events-niet-na-mi/","title":"PARADISE-MI: sacubitril/valsartan vermindert coronaire events niet na MI","published":"2022-12-06","doi":"10.1161/CIRCULATIONAHA.122.060841","journal":"Circulation","significance":7},{"url":"https://hartvaat.nl/2022/10/04/paradise-mi-sacubitril-valsartan-versus-ramipril-na-acuut-mi-echocardiografie/","title":"PARADISE-MI: sacubitril/valsartan versus ramipril na acuut MI — echocardiografie","published":"2022-10-04","doi":"10.1161/CIRCULATIONAHA.122.059210","journal":"Circulation","significance":7}]},{"trial":"TRANSFORM-HF","count":3,"first_published":"2023-01-17","last_published":"2024-02-01","articles":[{"url":"https://hartvaat.nl/2024/02/01/transform-hf-torsemide-versus-furosemide-bij-nieuw-vs-chronisch-hartfalen/","title":"TRANSFORM-HF: torsemide versus furosemide bij nieuw vs chronisch hartfalen","published":"2024-02-01","doi":"10.1001/jamacardio.2023.4776","journal":"JAMA cardiology","significance":6},{"url":"https://hartvaat.nl/2023/07/11/transform-hf-torsemide-versus-furosemide-geen-verschil-in-symptomen/","title":"TRANSFORM-HF: torsemide versus furosemide — geen verschil in symptomen","published":"2023-07-11","doi":"10.1161/CIRCULATIONAHA.123.064842","journal":"Circulation","significance":7},{"url":"https://hartvaat.nl/2023/01/17/transform-hf-torsemide-biedt-geen-overlevingsvoordeel-boven-furosemide/","title":"TRANSFORM-HF: torsemide biedt geen overlevingsvoordeel boven furosemide","published":"2023-01-17","doi":"10.1001/jama.2022.23924","journal":"JAMA","significance":9}]},{"trial":"USPSTF","count":3,"first_published":"2022-07-26","last_published":"2023-09-19","articles":[{"url":"https://hartvaat.nl/2023/09/19/uspstf-screening-op-hypertensieve-zwangerschapsstoornissen-aanbevolen/","title":"USPSTF: screening op hypertensieve zwangerschapsstoornissen aanbevolen","published":"2023-09-19","doi":"10.1001/jama.2023.16991","journal":"JAMA","significance":7},{"url":"https://hartvaat.nl/2023/07/18/uspstf-screening-op-lipidestoornissen-bij-kinderen-en-adolescenten/","title":"USPSTF: screening op lipidestoornissen bij kinderen en adolescenten","published":"2023-07-18","doi":"10.1001/jama.2023.11330","journal":"JAMA","significance":7},{"url":"https://hartvaat.nl/2022/07/26/uspstf-gedragsinterventies-voor-gezonde-leefstijl-bij-cardiovasculaire-preventie/","title":"USPSTF: gedragsinterventies voor gezonde leefstijl bij cardiovasculaire preventie","published":"2022-07-26","doi":"10.1001/jama.2022.10951","journal":"JAMA","significance":8}]},{"trial":"VICTOR","count":3,"first_published":"2025-09-27","last_published":"2026-02-11","articles":[{"url":"https://hartvaat.nl/2026/02/11/victor-vericiguat-en-mortaliteit-bij-hfref-definitieve-analyse/","title":"VICTOR: vericiguat en mortaliteit bij HFrEF — definitieve analyse","published":"2026-02-11","doi":"10.1093/eurheartj/ehaf655","journal":"European heart journal","significance":8},{"url":"https://hartvaat.nl/2025/12/16/victor-vericiguat-en-totale-hartfalengebeurtenissen-bij-stabiel-hfref/","title":"VICTOR: vericiguat en totale hartfalengebeurtenissen bij stabiel HFrEF","published":"2025-12-16","doi":"10.1016/j.jacc.2025.08.051","journal":"Journal of the American College of Cardiology","significance":6},{"url":"https://hartvaat.nl/2025/09/27/victor-vericiguat-bij-chronisch-hfref-dubbelblinde-fase-3b-trial/","title":"VICTOR: vericiguat bij chronisch HFrEF — dubbelblinde fase 3b trial","published":"2025-09-27","doi":"10.1016/S0140-6736(25)01665-4","journal":"Lancet (London, England)","significance":7}]},{"trial":"CADENCE","count":2,"first_published":"2026-04-25","last_published":"2026-05-12","articles":[{"url":"https://hartvaat.nl/2026/05/12/cadence-sotatercept-verlaagt-pulmonale-vaatweerstand-bij-gecombineerde-pre-postc/","title":"CADENCE: sotatercept verlaagt pulmonale vaatweerstand bij gecombineerde pre/postcapillaire PH bij HFpEF","published":"2026-05-12","doi":"10.1161/CIRCULATIONAHA.126.079918","journal":"Circulation","significance":9},{"url":"https://hartvaat.nl/2026/03/29/cadence-sotatercept-verlaagt-pulmonale-vaatweerstand-bij-gecombineerde-pulmonale/","title":"CADENCE: sotatercept verlaagt pulmonale vaatweerstand bij gecombineerde pulmonale hypertensie bij HFpEF","published":"2026-04-25","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.079918","journal":"Circulation","significance":9}]},{"trial":"DECAAF II","count":2,"first_published":"2023-08-02","last_published":"2024-05-02","articles":[{"url":"https://hartvaat.nl/2024/05/02/decaaf-ii-af-last-en-symptoomreductie-na-ablatie/","title":"DECAAF II: AF-last en symptoomreductie na ablatie","published":"2024-05-02","doi":"10.1093/europace/euae104","journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","significance":5},{"url":"https://hartvaat.nl/2023/08/02/decaaf-ii-fibroselocatie-beinvloedt-af-recidief-na-ablatie/","title":"DECAAF II: fibroselocatie beïnvloedt AF-recidief na ablatie","published":"2023-08-02","doi":"10.1093/europace/euad199","journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","significance":6}]},{"trial":"DECISION","count":2,"first_published":"2026-05-10","last_published":"2026-06-25","articles":[{"url":"https://hartvaat.nl/2026/05/10/decision-trial-digoxine-staken-bij-hartfalen-leidt-tot-zevenvoudige-stijging-in-/","title":"DECISION-trial: digoxine staken bij hartfalen leidt tot zevenvoudige stijging in HF-events binnen 6 weken","published":"2026-06-25","doi":"10.1093/eurheartj/ehag385","journal":"European heart journal","significance":8},{"url":"https://hartvaat.nl/2026/05/10/decision-lage-dosis-digoxine-mist-primair-eindpunt-bij-hf-m-ref-maar-suggereert-/","title":"DECISION: lage-dosis digoxine mist primair eindpunt bij HF(m)rEF, maar suggereert minder verslechterende hartfalenevents","published":"2026-05-10","doi":"10.1038/s41591-026-04406-6","journal":"Nature Medicine","significance":9}]},{"trial":"EMPACT-MI","count":2,"first_published":"2024-05-21","last_published":"2024-06-11","articles":[{"url":"https://hartvaat.nl/2024/06/11/empact-mi-lv-functie-congestie-en-empagliflozine-effect-na-mi/","title":"EMPACT-MI: LV-functie, congestie en empagliflozine-effect na MI","published":"2024-06-11","doi":"10.1016/j.jacc.2024.03.405","journal":"Journal of the American College of Cardiology","significance":6},{"url":"https://hartvaat.nl/2024/05/21/empact-mi-empagliflozine-en-hartfalenuitkomsten-na-mi/","title":"EMPACT-MI: empagliflozine en hartfalenuitkomsten na MI","published":"2024-05-21","doi":"10.1161/CIRCULATIONAHA.124.069217","journal":"Circulation","significance":7}]},{"trial":"EMPULSE","count":2,"first_published":"2022-07-26","last_published":"2023-01-01","articles":[{"url":"https://hartvaat.nl/2023/01/01/empulse-empagliflozine-verbetert-decongestie-bij-acuut-hartfalen/","title":"EMPULSE: empagliflozine verbetert decongestie bij acuut hartfalen","published":"2023-01-01","doi":"10.1093/eurheartj/ehac530","journal":"European heart journal","significance":8},{"url":"https://hartvaat.nl/2022/07/26/empulse-empagliflozine-verbetert-symptomen-en-kwaliteit-van-leven-bij-acuut-hart/","title":"EMPULSE: empagliflozine verbetert symptomen en kwaliteit van leven bij acuut hartfalen","published":"2022-07-26","doi":"10.1161/CIRCULATIONAHA.122.059725","journal":"Circulation","significance":9}]},{"trial":"GRADE","count":2,"first_published":"2022-09-22","last_published":"2024-03-26","articles":[{"url":"https://hartvaat.nl/2024/03/26/grade-cv-uitkomsten-van-glucoseverlagende-middelen-bij-type-2-diabetes/","title":"GRADE: CV-uitkomsten van glucoseverlagende middelen bij type 2 diabetes","published":"2024-03-26","doi":"10.1161/CIRCULATIONAHA.123.066604","journal":"Circulation","significance":7},{"url":"https://hartvaat.nl/2022/09/22/grade-vergelijking-glucoseverlagende-middelen-op-microvasculaire-en-cv-uitkomste/","title":"GRADE: vergelijking glucoseverlagende middelen op microvasculaire en CV-uitkomsten","published":"2022-09-22","doi":"10.1056/NEJMoa2200436","journal":"The New England journal of medicine","significance":9}]},{"trial":"OCEANIC-AF","count":2,"first_published":"2025-01-02","last_published":"2025-06-01","articles":[{"url":"https://hartvaat.nl/2025/06/01/oceanic-af-asundexian-naar-eerder-oac-gebruik/","title":"OCEANIC-AF: asundexian naar eerder OAC-gebruik","published":"2025-06-01","doi":"10.1001/jamacardio.2025.0277","journal":"JAMA cardiology","significance":5},{"url":"https://hartvaat.nl/2025/01/02/oceanic-af-asundexian-versus-apixaban-bij-af-nejm/","title":"OCEANIC-AF: asundexian versus apixaban bij AF — NEJM","published":"2025-01-02","doi":"10.1056/NEJMoa2407105","journal":"The New England journal of medicine","significance":10}]},{"trial":"POP-HT","count":2,"first_published":"2023-11-28","last_published":"2024-02-13","articles":[{"url":"https://hartvaat.nl/2024/02/13/pop-ht-bloeddrukzelfmanagement-verbetert-cardiale-remodelling-na-hypertensieve-z/","title":"POP-HT: bloeddrukzelfmanagement verbetert cardiale remodelling na hypertensieve zwangerschap","published":"2024-02-13","doi":"10.1161/CIRCULATIONAHA.123.067597","journal":"Circulation","significance":7},{"url":"https://hartvaat.nl/2023/11/28/pop-ht-zelfmanagement-van-bloeddruk-na-hypertensieve-zwangerschap-jama-rct/","title":"POP-HT: zelfmanagement van bloeddruk na hypertensieve zwangerschap — JAMA RCT","published":"2023-11-28","doi":"10.1001/jama.2023.21523","journal":"JAMA","significance":7}]},{"trial":"POST-PCI","count":2,"first_published":"2022-09-08","last_published":"2024-03-01","articles":[{"url":"https://hartvaat.nl/2024/03/01/post-pci-routine-stresstesten-bij-diabetespatienten-na-pci-niet-zinvol/","title":"POST-PCI: routine stresstesten bij diabetespatiënten na PCI niet zinvol","published":"2024-03-01","doi":"10.1093/eurheartj/ehad722","journal":"European heart journal","significance":7},{"url":"https://hartvaat.nl/2022/09/08/post-pci-routine-functionele-testen-versus-standaardzorg-na-pci-bij-hoog-risico/","title":"POST-PCI: routine functionele testen versus standaardzorg na PCI bij hoog risico","published":"2022-09-08","doi":"10.1056/NEJMoa2208335","journal":"The New England journal of medicine","significance":8}]},{"trial":"PRAISE-MR","count":2,"first_published":"2026-05-10","last_published":"2026-07-09","articles":[{"url":"https://hartvaat.nl/2026/05/09/praise-mr-sacubitril-valsartan-verbetert-inspanningshemodynamica-bij-hfpef-met-a/","title":"PRAISE-MR: sacubitril/valsartan verbetert inspanningshemodynamica bij HFpEF met atriale functionele mitralis-insufficiëntie","published":"2026-07-09","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.080833","journal":"Circulation","significance":8},{"url":"https://hartvaat.nl/2026/05/09/praise-mr-sacubitril-valsartan-verbetert-inspanningshemodynamiek-bij-hfpef-met-a/","title":"PRAISE-MR: sacubitril-valsartan verbetert inspanningshemodynamiek bij HFpEF met atriale mitralisinsufficiëntie","published":"2026-05-10","doi":"10.1161/CIRCULATIONAHA.126.080833","journal":"Circulation","significance":9}]},{"trial":"PREVENT","count":2,"first_published":"2024-05-04","last_published":"2025-08-21","articles":[{"url":"https://hartvaat.nl/2025/08/21/prevent-langetermijn-follow-up-van-preventieve-pci-bij-kwetsbare-plaques/","title":"PREVENT: langetermijn follow-up van preventieve PCI bij kwetsbare plaques","published":"2025-08-21","doi":"10.1093/eurheartj/ehaf273","journal":"European heart journal","significance":8},{"url":"https://hartvaat.nl/2024/05/04/prevent-preventieve-pci-versus-medicatie-bij-kwetsbare-coronaire-plaques-lancet/","title":"PREVENT: preventieve PCI versus medicatie bij kwetsbare coronaire plaques — Lancet","published":"2024-05-04","doi":"10.1016/S0140-6736(24)00413-6","journal":"Lancet (London, England)","significance":9}]},{"trial":"REDUCE-AMI","count":2,"first_published":"2024-10-10","last_published":"2025-08-01","articles":[{"url":"https://hartvaat.nl/2025/08/01/reduce-ami-betablokker-interruptie-en-bloeddruk-hartfrequentie-effecten-na-mi/","title":"REDUCE-AMI: bètablokker-interruptie en bloeddruk/hartfrequentie-effecten na MI","published":"2025-08-01","doi":"10.1093/eurheartj/ehaf170","journal":"European heart journal","significance":6},{"url":"https://hartvaat.nl/2024/10/10/reduce-ami-betablokkers-na-mi-met-behouden-ef-niet-nodig-bevestiging/","title":"REDUCE-AMI: bètablokkers na MI met behouden EF niet nodig — bevestiging","published":"2024-10-10","doi":"10.1056/NEJMoa2404204","journal":"The New England journal of medicine","significance":10}]},{"trial":"RENOVATE-COMPLEX-PCI","count":2,"first_published":"2023-05-04","last_published":"2024-05-01","articles":[{"url":"https://hartvaat.nl/2024/05/01/renovate-complex-pci-beeldvorming-geleide-pci-bij-vrouwen-versus-mannen/","title":"RENOVATE-COMPLEX-PCI: beeldvorming-geleide PCI bij vrouwen versus mannen","published":"2024-05-01","doi":"10.1001/jamacardio.2024.0291","journal":"JAMA cardiology","significance":6},{"url":"https://hartvaat.nl/2023/05/04/renovate-complex-pci-intravasculaire-beeldvorming-versus-angiografie-bij-complex/","title":"RENOVATE-COMPLEX-PCI: intravasculaire beeldvorming versus angiografie bij complexe PCI","published":"2023-05-04","doi":"10.1056/NEJMoa2216607","journal":"The New England journal of medicine","significance":9}]},{"trial":"SOUL","count":2,"first_published":"2025-05-29","last_published":"2025-06-10","articles":[{"url":"https://hartvaat.nl/2025/06/10/soul-oraal-semaglutide-cv-voordeel-naar-sglt2i-gebruik/","title":"SOUL: oraal semaglutide CV-voordeel naar SGLT2i-gebruik","published":"2025-06-10","doi":"10.1161/CIRCULATIONAHA.125.074545","journal":"Circulation","significance":7},{"url":"https://hartvaat.nl/2025/05/29/soul-oraal-semaglutide-en-cv-uitkomsten-bij-hoogrisico-type-2-diabetes-nejm/","title":"SOUL: oraal semaglutide en CV-uitkomsten bij hoogrisico type 2 diabetes — NEJM","published":"2025-05-29","doi":"10.1056/NEJMoa2501006","journal":"The New England journal of medicine","significance":10}]},{"trial":"STEP-HFpEF","count":2,"first_published":"2023-09-21","last_published":"2024-08-27","articles":[{"url":"https://hartvaat.nl/2024/08/27/step-hfpef-semaglutide-even-effectief-bij-mannen-en-vrouwen/","title":"STEP-HFpEF: semaglutide even effectief bij mannen en vrouwen","published":"2024-08-27","doi":"10.1016/j.jacc.2024.06.001","journal":"Journal of the American College of Cardiology","significance":6},{"url":"https://hartvaat.nl/2023/09/21/step-hfpef-semaglutide-bij-hfpef-en-obesitas-nejm/","title":"STEP-HFpEF: semaglutide bij HFpEF en obesitas — NEJM","published":"2023-09-21","doi":"10.1056/NEJMoa2306963","journal":"The New England journal of medicine","significance":10}]},{"trial":"UF-CARE","count":2,"first_published":"2026-05-11","last_published":"2026-06-25","articles":[{"url":"https://hartvaat.nl/2026/05/09/uf-care-trial-ultrafiltratie-bij-type-2-cardiorenaal-syndroom-geen-significante-/","title":"UF-CARE-trial: ultrafiltratie bij type-2 cardiorenaal syndroom geen significante winst (kleine, onderpowered RCT)","published":"2026-06-25","doi":"10.1093/eschf/xvag133","journal":"ESC heart failure","significance":6},{"url":"https://hartvaat.nl/2026/05/09/uf-care-ultrafiltratie-bij-type-2-cardiorenaal-syndroom-mist-primair-eindpunt-in/","title":"UF-CARE: ultrafiltratie bij type-2 cardiorenaal syndroom mist primair eindpunt in kleine Franse RCT","published":"2026-05-11","doi":"10.1093/eschf/xvag133","journal":"ESC Heart Failure","significance":6}]},{"trial":"VESALIUS-CV","count":2,"first_published":"2026-03-28","last_published":"2026-06-03","articles":[{"url":"https://hartvaat.nl/2026/05/25/vesalius-cv-lp-a-voorspelt-risico-evolocumab-werkt-ongeacht-uitgangswaarde/","title":"VESALIUS-CV: Lp(a) voorspelt risico, evolocumab werkt ongeacht uitgangswaarde","published":"2026-06-03","doi":"10.1161/CIRCULATIONAHA.126.080999","journal":"Circulation","significance":8},{"url":"https://hartvaat.nl/2026/03/28/vesalius-cv-evolocumab-verlaagt-risico-op-eerste-cardiovasculair-event-met-31-bi/","title":"VESALIUS-CV: evolocumab verlaagt risico op eerste cardiovasculair event met 31% bij patiënten zonder significant atherosclerose","published":"2026-03-28","doi":"https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2026.4521","journal":"JAMA","significance":9}]},{"trial":"ABYSS","count":1,"first_published":"2024-04-18","last_published":"2024-04-18","articles":[{"url":"https://hartvaat.nl/2024/04/18/abyss-betablokkers-na-mi-met-behouden-ef-niet-nodig-nejm/","title":"ABYSS: bètablokkers na MI met behouden EF niet nodig — NEJM","published":"2024-04-18","doi":"10.1056/NEJMoa2401479","journal":"The New England journal of medicine","significance":10}]},{"trial":"ACACIA-HCM","count":1,"first_published":"2026-08-28","last_published":"2026-08-28","articles":[{"url":"https://hartvaat.nl/2026/08/28/acacia-hcm-aficamten-verbetert-symptomen-en-inspanningscapaciteit-bij-niet-obstr/","title":"ACACIA-HCM: aficamten verbetert symptomen en inspanningscapaciteit bij niet-obstructieve HCM, de eerste positieve trial ooit in deze groep","published":"2026-08-28","doi":"10.1056/NEJMoa2603021","journal":"New England Journal of Medicine","significance":8}]},{"trial":"ACHIEVE","count":1,"first_published":"2025-08-16","last_published":"2025-08-16","articles":[{"url":"https://hartvaat.nl/2025/08/16/achieve-spironolacton-bij-dialysepatienten-internationale-rct/","title":"ACHIEVE: spironolacton bij dialysepatiënten — internationale RCT","published":"2025-08-16","doi":"10.1016/S0140-6736(25)01198-5","journal":"Lancet (London, England)","significance":7}]},{"trial":"ADAPT-CEC","count":1,"first_published":"2026-04-28","last_published":"2026-04-28","articles":[{"url":"https://hartvaat.nl/2026/03/30/adapt-cec-adaptief-ai-algoritme-voor-cardiovasculaire-event-adjudicatie-in-klini/","title":"ADAPT-CEC: adaptief AI-algoritme voor cardiovasculaire event-adjudicatie in klinische trials","published":"2026-04-28","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.080072","journal":"Circulation","significance":6}]},{"trial":"ADAPTABLE","count":1,"first_published":"2024-09-01","last_published":"2024-09-01","articles":[{"url":"https://hartvaat.nl/2024/09/01/adaptable-bijdrage-van-klinische-trial-data-naar-databron/","title":"ADAPTABLE: bijdrage van klinische trial-data naar databron","published":"2024-09-01","doi":"10.1001/jamacardio.2024.2019","journal":"JAMA cardiology","significance":5}]},{"trial":"ADVENT","count":1,"first_published":"2023-11-02","last_published":"2023-11-02","articles":[{"url":"https://hartvaat.nl/2023/11/02/advent-pulsed-field-ablatie-non-inferieur-aan-thermale-ablatie-bij-af-nejm/","title":"ADVENT: pulsed field ablatie non-inferieur aan thermale ablatie bij AF — NEJM","published":"2023-11-02","doi":"10.1056/NEJMoa2307291","journal":"The New England journal of medicine","significance":9}]},{"trial":"AEGIS-II","count":1,"first_published":"2024-05-02","last_published":"2024-05-02","articles":[{"url":"https://hartvaat.nl/2024/05/02/aegis-ii-apoa1-infusie-na-acuut-mi-verbetert-uitkomsten-niet-nejm/","title":"AEGIS-II: apoA1-infusie na acuut MI verbetert uitkomsten niet — NEJM","published":"2024-05-02","doi":"10.1056/NEJMoa2400969","journal":"The New England journal of medicine","significance":8}]},{"trial":"AFFIRM-AHF","count":1,"first_published":"2023-05-30","last_published":"2023-05-30","articles":[{"url":"https://hartvaat.nl/2023/05/30/affirm-ahf-hemoglobine-beinvloedt-iv-ijzereffect-bij-acuut-hartfalen/","title":"AFFIRM-AHF: hemoglobine beïnvloedt IV-ijzereffect bij acuut hartfalen","published":"2023-05-30","doi":"10.1161/CIRCULATIONAHA.122.060757","journal":"Circulation","significance":6}]},{"trial":"AFLOAT","count":1,"first_published":"2024-11-19","last_published":"2024-11-19","articles":[{"url":"https://hartvaat.nl/2024/11/19/afloat-flecainide-voorkomt-af-na-pfo-sluiting-rct/","title":"AFLOAT: flecaïnide voorkomt AF na PFO-sluiting — RCT","published":"2024-11-19","doi":"10.1161/CIRCULATIONAHA.124.071186","journal":"Circulation","significance":7}]},{"trial":"ALL-HEART","count":1,"first_published":"2022-10-08","last_published":"2022-10-08","articles":[{"url":"https://hartvaat.nl/2022/10/08/all-heart-allopurinol-verbetert-cv-uitkomsten-niet-bij-ischemische-hartziekte/","title":"ALL-HEART: allopurinol verbetert CV-uitkomsten niet bij ischemische hartziekte","published":"2022-10-08","doi":"10.1016/S0140-6736(22)01657-9","journal":"Lancet (London, England)","significance":8}]},{"trial":"ALONE-AF","count":1,"first_published":"2025-10-14","last_published":"2025-10-14","articles":[{"url":"https://hartvaat.nl/2025/10/14/alone-af-langetermijn-anticoagulatieonthouding-na-af-ablatie-rct/","title":"ALONE-AF: langetermijn anticoagulatieonthouding na AF-ablatie — RCT","published":"2025-10-14","doi":"10.1001/jama.2025.14679","journal":"JAMA","significance":8}]},{"trial":"AMALFI","count":1,"first_published":"2025-10-21","last_published":"2025-10-21","articles":[{"url":"https://hartvaat.nl/2025/10/21/amalfi-remote-screening-voor-asymptomatisch-af-gerandomiseerde-trial/","title":"AMALFI: remote screening voor asymptomatisch AF — gerandomiseerde trial","published":"2025-10-21","doi":"10.1001/jama.2025.15440","journal":"JAMA","significance":7}]},{"trial":"AMETHYST","count":1,"first_published":"2024-10-01","last_published":"2024-10-01","articles":[{"url":"https://hartvaat.nl/2024/10/01/amethyst-verinurad-plus-allopurinol-bij-hfpef-negatieve-trial/","title":"AMETHYST: verinurad plus allopurinol bij HFpEF — negatieve trial","published":"2024-10-01","doi":"10.1001/jamacardio.2024.2435","journal":"JAMA cardiology","significance":6}]},{"trial":"AMPLITUDE-O","count":1,"first_published":"2023-03-28","last_published":"2023-03-28","articles":[{"url":"https://hartvaat.nl/2023/03/28/amplitude-o-dosisrespons-van-efpeglenatide-op-cv-uitkomsten-bij-diabetes/","title":"AMPLITUDE-O: dosisrespons van efpeglenatide op CV-uitkomsten bij diabetes","published":"2023-03-28","doi":"10.1161/CIRCULATIONAHA.122.063716","journal":"Circulation","significance":6}]},{"trial":"ANDAMAN","count":1,"first_published":"2026-02-11","last_published":"2026-02-11","articles":[{"url":"https://hartvaat.nl/2026/02/11/andaman-aspirinedosering-na-acs-met-verdenking-aspirineresistentie/","title":"ANDAMAN: aspirinedosering na ACS met verdenking aspirineresistentie","published":"2026-02-11","doi":"10.1093/eurheartj/ehaf680","journal":"European heart journal","significance":6}]},{"trial":"ANNEXA-I","count":1,"first_published":"2024-05-16","last_published":"2024-05-16","articles":[{"url":"https://hartvaat.nl/2024/05/16/annexa-i-andexanet-alfa-bij-factor-xa-remmer-geassocieerde-intracerebrale-bloedi/","title":"ANNEXA-I: andexanet alfa bij factor Xa-remmer-geassocieerde intracerebrale bloeding — NEJM","published":"2024-05-16","doi":"10.1056/NEJMoa2313040","journal":"The New England journal of medicine","significance":10}]},{"trial":"ANSWER-HF","count":1,"first_published":"2026-03-17","last_published":"2026-03-17","articles":[{"url":"https://hartvaat.nl/2026/03/17/answer-hf-sacubitril-valsartan-versus-enalapril-bij-chagas-hf-primaire-resultate/","title":"ANSWER-HF: sacubitril/valsartan versus enalapril bij Chagas-HF — primaire resultaten","published":"2026-03-17","doi":"10.1016/j.jacc.2025.10.053","journal":"Journal of the American College of Cardiology","significance":7}]},{"trial":"APERITIF","count":1,"first_published":"2026-03-01","last_published":"2026-03-01","articles":[{"url":"https://hartvaat.nl/2026/02/25/aperitif-trial-laaggedoseerd-rivaroxaban-voorkomt-linkerventrikeltrombose-na-voo/","title":"APERITIF-trial: laaggedoseerd rivaroxaban voorkomt linkerventrikeltrombose na voorwandinfarct","published":"2026-03-01","doi":"10.1001/jamacardio.2026.0026","journal":"JAMA cardiology","significance":7}]},{"trial":"ARIC","count":1,"first_published":"2026-04-24","last_published":"2026-04-24","articles":[{"url":"https://hartvaat.nl/2026/04/01/aric-ckm-syndroom-stadiering-voorspelt-hartfalen-risico-bij-ouderen-ook-met-subk/","title":"ARIC: CKM-syndroom stadiëring voorspelt hartfalen-risico bij ouderen — ook met subklinisch echoprofiel","published":"2026-04-24","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077894","journal":"Circulation","significance":8}]},{"trial":"AROMI","count":1,"first_published":"2023-10-12","last_published":"2023-10-12","articles":[{"url":"https://hartvaat.nl/2023/10/12/aromi-prehospitale-copeptine-versnelt-mi-uitsluiting/","title":"AROMI: prehospitale copeptine versnelt MI-uitsluiting","published":"2023-10-12","doi":"10.1093/eurheartj/ehad447","journal":"European heart journal","significance":7}]},{"trial":"ARREST-AF","count":1,"first_published":"2025-12-01","last_published":"2025-12-01","articles":[{"url":"https://hartvaat.nl/2025/12/01/arrest-af-agressieve-risicofactorreductie-en-ablatie-uitkomsten/","title":"ARREST-AF: agressieve risicofactorreductie en ablatie-uitkomsten","published":"2025-12-01","doi":"10.1001/jamacardio.2025.4007","journal":"JAMA cardiology","significance":7}]},{"trial":"ASPREE","count":1,"first_published":"2025-12-09","last_published":"2025-12-09","articles":[{"url":"https://hartvaat.nl/2025/12/09/aspree-cardiale-stress-en-bloeddrukmanagement-bij-ouderen/","title":"ASPREE: cardiale stress en bloeddrukmanagement bij ouderen","published":"2025-12-09","doi":"10.1161/CIRCULATIONAHA.125.076263","journal":"Circulation","significance":6}]},{"trial":"AWARE","count":1,"first_published":"2023-05-01","last_published":"2023-05-01","articles":[{"url":"https://hartvaat.nl/2023/05/01/aware-uitgebreide-ablatie-vermindert-af-recidief-niet-boven-standaard-pvi/","title":"AWARE: uitgebreide ablatie vermindert AF-recidief niet boven standaard PVI","published":"2023-05-01","doi":"10.1001/jamacardio.2023.0212","journal":"JAMA cardiology","significance":7}]},{"trial":"AXADIA-AFNET 8","count":1,"first_published":"2023-01-24","last_published":"2023-01-24","articles":[{"url":"https://hartvaat.nl/2023/01/24/axadia-afnet-8-apixaban-versus-vka-bij-af-op-hemodialyse/","title":"AXADIA-AFNET 8: apixaban versus VKA bij AF op hemodialyse","published":"2023-01-24","doi":"10.1161/CIRCULATIONAHA.122.062779","journal":"Circulation","significance":7}]},{"trial":"AXAFA-AFNET 5","count":1,"first_published":"2017-01-01","last_published":"2017-01-01","articles":[{"url":"https://hartvaat.nl/2017/01/01/axafa-afnet-5-apixaban-versus-vka-bij-af-ablatie-studieprotocol/","title":"AXAFA-AFNET 5: apixaban versus VKA bij AF-ablatie — studieprotocol","published":"2017-01-01","doi":"10.1093/europace/euw368","journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","significance":5}]},{"trial":"AZALEA-TIMI 71","count":1,"first_published":"2025-06-17","last_published":"2025-06-17","articles":[{"url":"https://hartvaat.nl/2025/06/17/azalea-timi-71-langwerkende-factor-xi-remmer-en-periprocedurale-bloedingen/","title":"AZALEA-TIMI 71: langwerkende factor XI-remmer en periprocedurale bloedingen","published":"2025-06-17","doi":"10.1016/j.jacc.2025.04.018","journal":"Journal of the American College of Cardiology","significance":7}]},{"trial":"BEST-CLI","count":1,"first_published":"2023-05-27","last_published":"2023-05-27","articles":[{"url":"https://hartvaat.nl/2023/05/27/best-cli-veneuze-bypass-versus-endovasculair-bij-chronische-kritieke-ischemie/","title":"BEST-CLI: veneuze bypass versus endovasculair bij chronische kritieke ischemie","published":"2023-05-27","doi":"10.1016/S0140-6736(23)00462-2","journal":"Lancet (London, England)","significance":8}]},{"trial":"BEST-II","count":1,"first_published":"2023-09-05","last_published":"2023-09-05","articles":[{"url":"https://hartvaat.nl/2023/09/05/best-ii-bloeddrukmanagement-na-trombectomie-bij-cva-jama/","title":"BEST-II: bloeddrukmanagement na trombectomie bij CVA — JAMA","published":"2023-09-05","doi":"10.1001/jama.2023.14330","journal":"JAMA","significance":7}]},{"trial":"BIOVASC","count":1,"first_published":"2023-04-08","last_published":"2023-04-08","articles":[{"url":"https://hartvaat.nl/2023/04/08/biovasc-directe-versus-gestageerde-complete-revascularisatie-bij-acs-met-meervat/","title":"BIOVASC: directe versus gestageerde complete revascularisatie bij ACS met meervatslijden","published":"2023-04-08","doi":"10.1016/S0140-6736(23)00351-3","journal":"Lancet (London, England)","significance":8}]},{"trial":"BOX","count":1,"first_published":"2022-10-20","last_published":"2022-10-20","articles":[{"url":"https://hartvaat.nl/2022/10/20/box-bloeddrukdoelen-bij-comateuze-overlevenden-van-hartstilstand/","title":"BOX: bloeddrukdoelen bij comateuze overlevenden van hartstilstand","published":"2022-10-20","doi":"10.1056/NEJMoa2208687","journal":"The New England journal of medicine","significance":8}]},{"trial":"BUDAPEST-CRT Upgrade","count":1,"first_published":"2017-09-01","last_published":"2017-09-01","articles":[{"url":"https://hartvaat.nl/2017/09/01/budapest-crt-upgrade-study-studieontwerp-voor-crt-upgrade/","title":"BUDAPEST-CRT Upgrade Study: studieontwerp voor CRT-upgrade","published":"2017-09-01","doi":"10.1093/europace/euw193","journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","significance":5}]},{"trial":"C-MIC II","count":1,"first_published":"2026-03-03","last_published":"2026-03-03","articles":[{"url":"https://hartvaat.nl/2026/03/03/c-mic-ii-hartfunctie-inspanningscapaciteit-en-kwaliteit-van-leven-zijn-verwante-/","title":"C-MIC II: hartfunctie, inspanningscapaciteit en kwaliteit van leven zijn verwante maar aparte domeinen","published":"2026-03-03","doi":"10.1093/eschf/xvag102","journal":"ESC heart failure","significance":5}]},{"trial":"CAAN-AF","count":1,"first_published":"2026-07-14","last_published":"2026-07-14","articles":[{"url":"https://hartvaat.nl/2026/04/16/caan-af-av-knoopablatie-verbetert-crt-uitkomsten-bij-permanent-atriumfibrilleren/","title":"CAAN-AF: AV-knoopablatie verbetert CRT-uitkomsten bij permanent atriumfibrilleren niet","published":"2026-07-14","doi":"10.1093/eurheartj/ehag206","journal":"European heart journal","significance":7}]},{"trial":"CABANA","count":1,"first_published":"2022-08-16","last_published":"2022-08-16","articles":[{"url":"https://hartvaat.nl/2022/08/16/cabana-catheterablatie-bij-af-is-kosteneffectief-vergeleken-met-antiaritmica/","title":"CABANA: catheterablatie bij AF is kosteneffectief vergeleken met antiaritmica","published":"2022-08-16","doi":"10.1161/CIRCULATIONAHA.122.058575","journal":"Circulation","significance":7}]},{"trial":"CALCIFIED","count":1,"first_published":"2025-07-01","last_published":"2025-07-01","articles":[{"url":"https://hartvaat.nl/2025/07/01/calcified-oct-versus-angiografie-bij-pci-van-verkalkte-laesies/","title":"CALCIFIED: OCT versus angiografie bij PCI van verkalkte laesies","published":"2025-07-01","doi":"10.1001/jamacardio.2025.0741","journal":"JAMA cardiology","significance":7}]},{"trial":"CAMEO-DAPA","count":1,"first_published":"2023-09-05","last_published":"2023-09-05","articles":[{"url":"https://hartvaat.nl/2023/09/05/cameo-dapa-cardiale-en-metabole-effecten-van-dapagliflozine-bij-hfpef/","title":"CAMEO-DAPA: cardiale en metabole effecten van dapagliflozine bij HFpEF","published":"2023-09-05","doi":"10.1161/CIRCULATIONAHA.123.065134","journal":"Circulation","significance":6}]},{"trial":"CAPLA","count":1,"first_published":"2023-01-10","last_published":"2023-01-10","articles":[{"url":"https://hartvaat.nl/2023/01/10/capla-posterior-wand-isolatie-verbetert-uitkomst-niet-bij-persisterend-af/","title":"CAPLA: posterior wand-isolatie verbetert uitkomst niet bij persisterend AF","published":"2023-01-10","doi":"10.1001/jama.2022.23722","journal":"JAMA","significance":8}]},{"trial":"CASTLE-HTx","count":1,"first_published":"2023-10-12","last_published":"2023-10-12","articles":[{"url":"https://hartvaat.nl/2023/10/12/castle-htx-af-ablatie-bij-eindstadium-hartfalen-nejm/","title":"CASTLE-HTx: AF-ablatie bij eindstadium hartfalen — NEJM","published":"2023-10-12","doi":"10.1056/NEJMoa2306037","journal":"The New England journal of medicine","significance":10}]},{"trial":"CAVIAR","count":1,"first_published":"2026-01-06","last_published":"2026-01-06","articles":[{"url":"https://hartvaat.nl/2026/01/06/caviar-alirocumab-bij-cardiale-allograft-vasculopathie-na-harttransplantatie/","title":"CAVIAR: alirocumab bij cardiale allograft vasculopathie na harttransplantatie","published":"2026-01-06","doi":"10.1161/CIRCULATIONAHA.125.077603","journal":"Circulation","significance":7}]},{"trial":"CHAMPION-AF","count":1,"first_published":"2026-03-29","last_published":"2026-03-29","articles":[{"url":"https://hartvaat.nl/2026/03/28/champion-af-watchman-flx-non-inferieur-aan-noac-s-en-superieur-in-bloedingsreduc/","title":"CHAMPION-AF: WATCHMAN FLX non-inferieur aan NOAC's en superieur in bloedingsreductie bij atriumfibrilleren","published":"2026-03-29","doi":"https://www.nejm.org/doi/full/10.1056/NEJMoa2517213&rss=currentIssue","journal":"NEJM","significance":10}]},{"trial":"CHIPS","count":1,"first_published":"2016-11-01","last_published":"2016-11-01","articles":[{"url":"https://hartvaat.nl/2016/11/01/chips-trial-is-ernstige-hypertensie-in-de-zwangerschap-meer-dan-alleen-verhoogde/","title":"CHIPS-trial: is ernstige hypertensie in de zwangerschap meer dan alleen verhoogde bloeddruk?","published":"2016-11-01","doi":"10.1161/HYPERTENSIONAHA.116.07862","journal":"Hypertension (Dallas, Tex. : 1979)","significance":6}]},{"trial":"CIRCA-DOSE","count":1,"first_published":"2024-02-16","last_published":"2024-02-16","articles":[{"url":"https://hartvaat.nl/2024/02/16/circa-dose-af-progressie-na-cryoablatie-versus-rf-ablatie/","title":"CIRCA-DOSE: AF-progressie na cryoablatie versus RF-ablatie","published":"2024-02-16","doi":"10.1093/eurheartj/ehad572","journal":"European heart journal","significance":6}]},{"trial":"CLEAR SYNERGY","count":1,"first_published":"2025-02-13","last_published":"2025-02-13","articles":[{"url":"https://hartvaat.nl/2025/02/13/clear-synergy-colchicine-bij-acuut-mi-nejm/","title":"CLEAR SYNERGY: colchicine bij acuut MI — NEJM","published":"2025-02-13","doi":"10.1056/NEJMoa2405922","journal":"The New England journal of medicine","significance":10}]},{"trial":"CLIP-HFpEF","count":1,"first_published":"2025-04-01","last_published":"2025-04-01","articles":[{"url":"https://hartvaat.nl/2025/04/01/clip-hfpef-cilostazol-bij-hfpef-gerandomiseerde-trial/","title":"CLIP-HFpEF: cilostazol bij HFpEF — gerandomiseerde trial","published":"2025-04-01","doi":"10.1002/ehf2.15162","journal":"ESC heart failure","significance":5}]},{"trial":"CLOROTIC","count":1,"first_published":"2023-02-01","last_published":"2023-02-01","articles":[{"url":"https://hartvaat.nl/2023/02/01/clorotic-thiazide-toevoegen-aan-lisdiureticum-bij-acuut-hartfalen/","title":"CLOROTIC: thiazide toevoegen aan lisdiureticum bij acuut hartfalen","published":"2023-02-01","doi":"10.1093/eurheartj/ehac689","journal":"European heart journal","significance":8}]},{"trial":"CLOSURE-AF","count":1,"first_published":"2026-03-26","last_published":"2026-03-26","articles":[{"url":"https://hartvaat.nl/2026/03/18/closure-af-sluiting-van-het-linker-hartoor-niet-non-inferieur-aan-medicamenteuze/","title":"CLOSURE-AF: sluiting van het linker hartoor niet non-inferieur aan medicamenteuze therapie bij atriumfibrilleren","published":"2026-03-26","doi":"https://www.nejm.org/doi/full/10.1056/NEJMoa2513310&rss=currentIssue","journal":"NEJM","significance":9}]},{"trial":"CMR GUIDE","count":1,"first_published":"2026-08-28","last_published":"2026-08-28","articles":[{"url":"https://hartvaat.nl/2026/08/28/cmr-guide-icd-bij-littekenweefsel-en-lvef-36-tot-50-procent-mist-het-primaire-ei/","title":"CMR GUIDE: ICD bij littekenweefsel en LVEF 36 tot 50 procent mist het primaire eindpunt, maar halveert plotse hartdood en helpt vooral onder de 70","published":"2026-08-28","doi":"10.1001/jama.2026.17078","journal":"JAMA","significance":7}]},{"trial":"COACT","count":1,"first_published":"2026-03-17","last_published":"2026-03-17","articles":[{"url":"https://hartvaat.nl/2025/01/01/coact-trial-langetermijnlessen-over-coronairangiografie-na-reanimatie/","title":"COACT-trial: langetermijnlessen over coronairangiografie na reanimatie","published":"2026-03-17","doi":"https://www.sciencedirect.com/science/article/pii/S073510972600224X?dgcid=rss_sd_all","journal":"JACC","significance":7}]},{"trial":"COAPT","count":1,"first_published":"2022-11-15","last_published":"2022-11-15","articles":[{"url":"https://hartvaat.nl/2022/11/15/coapt-mitraclip-vermindert-hospitalisaties-bij-secundaire-mr-en-hartfalen/","title":"COAPT: MitraClip vermindert hospitalisaties bij secundaire MR en hartfalen","published":"2022-11-15","doi":"10.1016/j.jacc.2022.08.803","journal":"Journal of the American College of Cardiology","significance":8}]},{"trial":"COLICA","count":1,"first_published":"2024-12-01","last_published":"2024-12-01","articles":[{"url":"https://hartvaat.nl/2024/12/01/colica-colchicine-bij-acuut-gedecompenseerd-hartfalen/","title":"COLICA: colchicine bij acuut gedecompenseerd hartfalen","published":"2024-12-01","doi":"10.1093/eurheartj/ehae538","journal":"European heart journal","significance":7}]},{"trial":"CONFIDENT-HFpEF","count":1,"first_published":"2026-07-20","last_published":"2026-07-20","articles":[{"url":"https://hartvaat.nl/2026/04/07/confident-hfpef-machine-learning-voorspelt-sterfte-en-opname-beter-dan-bestaande/","title":"CONFIDENT-HFpEF: machine-learning voorspelt sterfte en opname beter dan bestaande risicoscores","published":"2026-07-20","doi":"10.1093/eschf/xvag097","journal":"ESC heart failure","significance":6}]},{"trial":"CONNECT","count":1,"first_published":"2024-01-16","last_published":"2024-01-16","articles":[{"url":"https://hartvaat.nl/2024/01/16/connect-palliatieve-telezorg-verbetert-kwaliteit-van-leven-bij-hartfalen-jama/","title":"CONNECT: palliatieve telezorg verbetert kwaliteit van leven bij hartfalen — JAMA","published":"2024-01-16","doi":"10.1001/jama.2023.24035","journal":"JAMA","significance":7}]},{"trial":"CONVINCE","count":1,"first_published":"2024-07-13","last_published":"2024-07-13","articles":[{"url":"https://hartvaat.nl/2024/07/13/convince-langetermijn-colchicine-voor-preventie-van-recidief-niet-cardioembolisc/","title":"CONVINCE: langetermijn colchicine voor preventie van recidief niet-cardioembolisch CVA — Lancet","published":"2024-07-13","doi":"10.1016/S0140-6736(24)00968-1","journal":"Lancet (London, England)","significance":8}]},{"trial":"COOPERATIVE-PFA","count":1,"first_published":"2025-07-22","last_published":"2025-07-22","articles":[{"url":"https://hartvaat.nl/2025/07/22/cooperative-pfa-driearmige-gerandomiseerde-trial-van-pfa-versus-rf-versus-cryo/","title":"COOPERATIVE-PFA: driearmige gerandomiseerde trial van PFA versus RF versus cryo","published":"2025-07-22","doi":"10.1161/CIRCULATIONAHA.125.074427","journal":"Circulation","significance":8}]},{"trial":"CRADLE-4","count":1,"first_published":"2023-07-29","last_published":"2023-07-29","articles":[{"url":"https://hartvaat.nl/2023/07/29/cradle-4-geplande-bevalling-versus-afwachten-bij-laat-preterm-pre-eclampsie-in-l/","title":"CRADLE-4: geplande bevalling versus afwachten bij laat-preterm pre-eclampsie in LMIC's","published":"2023-07-29","doi":"10.1016/S0140-6736(23)00688-8","journal":"Lancet (London, England)","significance":7}]},{"trial":"CRRF-PeAF","count":1,"first_published":"2025-11-07","last_published":"2025-11-07","articles":[{"url":"https://hartvaat.nl/2025/11/07/crrf-peaf-cryoballon-versus-rf-ablatie-bij-persisterend-af/","title":"CRRF-PeAF: cryoballon versus RF-ablatie bij persisterend AF","published":"2025-11-07","doi":"10.1093/eurheartj/ehaf451","journal":"European heart journal","significance":7}]},{"trial":"CSL112","count":1,"first_published":"2016-12-13","last_published":"2016-12-13","articles":[{"url":"https://hartvaat.nl/2016/12/13/csl112-gereconstitueerd-apoliproteine-a-i-na-acuut-mi-veiligheid-en-verdraagbaar/","title":"CSL112: gereconstitueerd apoliproteïne A-I na acuut MI — veiligheid en verdraagbaarheid","published":"2016-12-13","doi":"10.1161/CIRCULATIONAHA.116.025687","journal":"Circulation","significance":6}]},{"trial":"CSP-SYNC","count":1,"first_published":"2025-09-01","last_published":"2025-09-01","articles":[{"url":"https://hartvaat.nl/2025/09/01/csp-sync-geleidingssysteempacing-versus-biventriculaire-pacing-voor-crt-rct/","title":"CSP-SYNC: geleidingssysteempacing versus biventriculaire pacing voor CRT — RCT","published":"2025-09-01","doi":"10.1093/europace/euaf192","journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","significance":8}]},{"trial":"CTS-AMI","count":1,"first_published":"2023-10-24","last_published":"2023-10-24","articles":[{"url":"https://hartvaat.nl/2023/10/24/cts-ami-tongxinluo-bij-acuut-mi-jama-mega-trial/","title":"CTS-AMI: Tongxinluo bij acuut MI — JAMA mega-trial","published":"2023-10-24","doi":"10.1001/jama.2023.19524","journal":"JAMA","significance":8}]},{"trial":"DAPA ACT HF-TIMI 68","count":1,"first_published":"2025-11-18","last_published":"2025-11-18","articles":[{"url":"https://hartvaat.nl/2025/11/18/dapa-act-hf-timi-68-dapagliflozine-bij-gehospitaliseerd-hartfalen-nejm/","title":"DAPA ACT HF-TIMI 68: dapagliflozine bij gehospitaliseerd hartfalen — NEJM","published":"2025-11-18","doi":"10.1161/CIRCULATIONAHA.125.076575","journal":"Circulation","significance":9}]},{"trial":"DAPA-HD","count":1,"first_published":"2026-06-29","last_published":"2026-06-29","articles":[{"url":"https://hartvaat.nl/2026/05/05/dapa-hd-eerste-gerandomiseerde-studie-naar-dapagliflozin-bij-hemodialyse-patient/","title":"DAPA-HD: eerste gerandomiseerde studie naar dapagliflozin bij hemodialyse-patiënten — opzet en achtergrond","published":"2026-06-29","doi":"10.1093/eschf/xvag104","journal":"ESC heart failure","significance":5}]},{"trial":"DAPA-HF","count":1,"first_published":"2024-05-21","last_published":"2024-05-21","articles":[{"url":"https://hartvaat.nl/2024/05/21/dapa-hf-dapagliflozine-en-dagen-in-volledige-gezondheid/","title":"DAPA-HF: dapagliflozine en dagen in volledige gezondheid","published":"2024-05-21","doi":"10.1016/j.jacc.2024.03.385","journal":"Journal of the American College of Cardiology","significance":6}]},{"trial":"DAPA-MI","count":1,"first_published":"2024-04-25","last_published":"2024-04-25","articles":[{"url":"https://hartvaat.nl/2024/04/25/dapa-mi-empagliflozine-na-acuut-mi-zonder-hf-of-diabetes-nejm/","title":"DAPA-MI: empagliflozine na acuut MI zonder HF of diabetes — NEJM","published":"2024-04-25","doi":"10.1056/NEJMoa2314051","journal":"The New England journal of medicine","significance":9}]},{"trial":"DARE-AF","count":1,"first_published":"2026-02-03","last_published":"2026-02-03","articles":[{"url":"https://hartvaat.nl/2026/02/03/dare-af-dapagliflozine-vermindert-vroeg-af-recidief-na-ablatie/","title":"DARE-AF: dapagliflozine vermindert vroeg AF-recidief na ablatie","published":"2026-02-03","doi":"10.1161/CIRCULATIONAHA.125.077447","journal":"Circulation","significance":8}]},{"trial":"DECAF","count":1,"first_published":"2026-01-27","last_published":"2026-01-27","articles":[{"url":"https://hartvaat.nl/2026/01/27/decaf-cafeinehoudende-koffie-en-af-gerandomiseerde-trial/","title":"DECAF: cafeïnehoudende koffie en AF — gerandomiseerde trial","published":"2026-01-27","doi":"10.1001/jama.2025.21056","journal":"JAMA","significance":7}]},{"trial":"DELTA-HF","count":1,"first_published":"2026-05-10","last_published":"2026-05-10","articles":[{"url":"https://hartvaat.nl/2026/05/10/delta-hf-thoracale-duct-lymfedecongestie-via-elym-systeem-haalbaar-bij-acute-har/","title":"DELTA-HF: thoracale-duct lymfedecongestie via eLym-systeem haalbaar bij acute hartfalen","published":"2026-05-10","doi":"10.1093/ejhf/xuag157","journal":"European Journal of Heart Failure","significance":7}]},{"trial":"DIAMOND","count":1,"first_published":"2022-11-01","last_published":"2022-11-01","articles":[{"url":"https://hartvaat.nl/2022/11/01/diamond-patiromer-maakt-raas-remmer-optitratie-bij-hfref-met-hyperkaliemie-mogel/","title":"DIAMOND: patiromer maakt RAAS-remmer-optitratie bij HFrEF met hyperkaliëmie mogelijk","published":"2022-11-01","doi":"10.1093/eurheartj/ehac401","journal":"European heart journal","significance":8}]},{"trial":"DRIVE","count":1,"first_published":"2024-06-04","last_published":"2024-06-04","articles":[{"url":"https://hartvaat.nl/2024/06/04/drive-remote-management-verbetert-richtlijnmedicatie-bij-hartfalen/","title":"DRIVE: remote management verbetert richtlijnmedicatie bij hartfalen","published":"2024-06-04","doi":"10.1161/CIRCULATIONAHA.124.069494","journal":"Circulation","significance":7}]},{"trial":"Dig-RHD","count":1,"first_published":"2026-05-10","last_published":"2026-05-10","articles":[{"url":"https://hartvaat.nl/2026/05/10/dig-rhd-digoxine-verlaagt-sterfte-en-hartfalen-bij-symptomatische-reumatische-ha/","title":"Dig-RHD: digoxine verlaagt sterfte en hartfalen bij symptomatische reumatische hartziekte","published":"2026-05-10","doi":"10.1001/jama.2026.7335","journal":"JAMA","significance":8}]},{"trial":"EARLY-UNLOAD","count":1,"first_published":"2023-11-14","last_published":"2023-11-14","articles":[{"url":"https://hartvaat.nl/2023/11/14/early-unload-vroege-lv-ontlading-bij-va-ecmo-gerandomiseerde-trial/","title":"EARLY-UNLOAD: vroege LV-ontlading bij VA-ECMO — gerandomiseerde trial","published":"2023-11-14","doi":"10.1161/CIRCULATIONAHA.123.066179","journal":"Circulation","significance":7}]},{"trial":"EAS FHSC","count":1,"first_published":"2026-06-04","last_published":"2026-06-04","articles":[{"url":"https://hartvaat.nl/2026/05/14/eas-fhsc-wereldwijd-onderzoek-toont-grote-variatie-in-genetische-fh-diagnostiek-/","title":"EAS FHSC: wereldwijd onderzoek toont grote variatie in genetische FH-diagnostiek — pleidooi voor standaardisatie","published":"2026-06-04","doi":"10.1093/eurjpc/zwag198","journal":"European journal of preventive cardiology","significance":7}]},{"trial":"EAST-AFNET4","count":1,"first_published":"2022-09-13","last_published":"2022-09-13","articles":[{"url":"https://hartvaat.nl/2022/09/13/east-afnet4-vroege-ritmecontrole-effectief-ook-bij-hoge-comorbiditeit/","title":"EAST-AFNET4: vroege ritmecontrole effectief ook bij hoge comorbiditeit","published":"2022-09-13","doi":"10.1161/CIRCULATIONAHA.122.060274","journal":"Circulation","significance":8}]},{"trial":"ECLS-SHOCK","count":1,"first_published":"2023-10-05","last_published":"2023-10-05","articles":[{"url":"https://hartvaat.nl/2023/10/05/ecls-shock-ecmo-bij-infarctgerelateerde-cardiogene-shock-nejm/","title":"ECLS-SHOCK: ECMO bij infarctgerelateerde cardiogene shock — NEJM","published":"2023-10-05","doi":"10.1056/NEJMoa2307227","journal":"The New England journal of medicine","significance":10}]},{"trial":"ECMO-CS","count":1,"first_published":"2023-02-07","last_published":"2023-02-07","articles":[{"url":"https://hartvaat.nl/2023/02/07/ecmo-cs-ecmo-bij-cardiogene-shock-verbetert-overleving-niet/","title":"ECMO-CS: ECMO bij cardiogene shock verbetert overleving niet","published":"2023-02-07","doi":"10.1161/CIRCULATIONAHA.122.062949","journal":"Circulation","significance":8}]},{"trial":"ECOG-ACRIN EAQ191","count":1,"first_published":"2026-07-07","last_published":"2026-07-07","articles":[{"url":"https://hartvaat.nl/2026/05/20/ecog-acrin-eaq191-intensieve-bloeddrukcontrole-tijdens-vegfr-tki-therapie-haalba/","title":"ECOG-ACRIN EAQ191: intensieve bloeddrukcontrole tijdens VEGFR-TKI-therapie haalbaar en veilig bij kankerpatiënten","published":"2026-07-07","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26016","journal":"Hypertension","significance":6}]},{"trial":"EFFORT","count":1,"first_published":"2024-06-11","last_published":"2024-06-11","articles":[{"url":"https://hartvaat.nl/2024/06/11/effort-ertugliflozine-bij-functionele-mitralisinsufficientie-en-hartfalen/","title":"EFFORT: ertugliflozine bij functionele mitralisinsufficiëntie en hartfalen","published":"2024-06-11","doi":"10.1161/CIRCULATIONAHA.124.069144","journal":"Circulation","significance":7}]},{"trial":"EHEART","count":1,"first_published":"2026-03-17","last_published":"2026-03-17","articles":[{"url":"https://hartvaat.nl/2025/01/01/eheart-trial-real-time-hartteam-verbetert-besluitvorming-bij-complexe-coronaire-/","title":"EHEART-trial: real-time hartteam verbetert besluitvorming bij complexe coronaire revascularisatie","published":"2026-03-17","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726000707?dgcid=rss_sd_all","journal":"JACC","significance":7}]},{"trial":"ELAN","count":1,"first_published":"2023-06-29","last_published":"2023-06-29","articles":[{"url":"https://hartvaat.nl/2023/06/29/elan-vroege-versus-late-anticoagulatie-na-cva-bij-af-nejm/","title":"ELAN: vroege versus late anticoagulatie na CVA bij AF — NEJM","published":"2023-06-29","doi":"10.1056/NEJMoa2303048","journal":"The New England journal of medicine","significance":10}]},{"trial":"EMERGE LAA","count":1,"first_published":"2026-06-25","last_published":"2026-06-25","articles":[{"url":"https://hartvaat.nl/2026/05/11/emerge-laa-amulet-occluder-in-12-180-patienten-96-succes-1-jaars-beroerte-1-6-re/","title":"EMERGE LAA: Amulet-occluder in 12.180 patiënten — 96% succes, 1-jaars beroerte 1,6% (real-world register)","published":"2026-06-25","doi":"10.1016/j.jcin.2026.02.016","journal":"JACC. Cardiovascular interventions","significance":8}]},{"trial":"EMMY","count":1,"first_published":"2022-11-01","last_published":"2022-11-01","articles":[{"url":"https://hartvaat.nl/2022/11/01/emmy-empagliflozine-na-acuut-myocardinfarct-verbetert-nt-probnp-en-remodelling/","title":"EMMY: empagliflozine na acuut myocardinfarct verbetert NT-proBNP en remodelling","published":"2022-11-01","doi":"10.1093/eurheartj/ehac494","journal":"European heart journal","significance":8}]},{"trial":"EMPA-HEART 2","count":1,"first_published":"2023-01-24","last_published":"2023-01-24","articles":[{"url":"https://hartvaat.nl/2023/01/24/empa-heart-2-empagliflozine-vermindert-lv-massa-niet-bij-patienten-zonder-diabet/","title":"EMPA-HEART 2: empagliflozine vermindert LV-massa niet bij patiënten zonder diabetes of HF","published":"2023-01-24","doi":"10.1161/CIRCULATIONAHA.122.062769","journal":"Circulation","significance":7}]},{"trial":"EMPA-KIDNEY","count":1,"first_published":"2023-01-12","last_published":"2023-01-12","articles":[{"url":"https://hartvaat.nl/2023/01/12/empa-kidney-empagliflozine-beschermt-nieren-bij-brede-ckd-populatie/","title":"EMPA-KIDNEY: empagliflozine beschermt nieren bij brede CKD-populatie","published":"2023-01-12","doi":"10.1056/NEJMoa2204233","journal":"The New England journal of medicine","significance":10}]},{"trial":"EMPAG-HF","count":1,"first_published":"2022-07-26","last_published":"2022-07-26","articles":[{"url":"https://hartvaat.nl/2022/07/26/empag-hf-vroege-empagliflozine-bij-acuut-hartfalen-verbetert-diurese/","title":"EMPAG-HF: vroege empagliflozine bij acuut hartfalen verbetert diurese","published":"2022-07-26","doi":"10.1161/CIRCULATIONAHA.122.059038","journal":"Circulation","significance":8}]},{"trial":"EMPATHY","count":1,"first_published":"2026-03-05","last_published":"2026-03-05","articles":[{"url":"https://hartvaat.nl/2026/03/05/empathy-hartfalentherapie-bij-patienten-met-gevorderde-kanker-en-palliatieve-zor/","title":"EMPATHY: hartfalentherapie bij patiënten met gevorderde kanker en palliatieve zorg","published":"2026-03-05","doi":"10.1093/eurheartj/ehaf705","journal":"European heart journal","significance":6}]},{"trial":"EMPERIAL","count":1,"first_published":"2025-04-07","last_published":"2025-04-07","articles":[{"url":"https://hartvaat.nl/2025/04/07/emperial-empagliflozine-bij-resistente-hypertensie-en-hfpef/","title":"EMPERIAL: empagliflozine bij resistente hypertensie en HFpEF","published":"2025-04-07","doi":"10.1093/eurheartj/ehae938","journal":"European heart journal","significance":7}]},{"trial":"ENCHANTED2/MT","count":1,"first_published":"2022-11-05","last_published":"2022-11-05","articles":[{"url":"https://hartvaat.nl/2022/11/05/enchanted2-mt-intensieve-bloeddrukverlaging-na-trombectomie-bij-cva-is-schadelij/","title":"ENCHANTED2/MT: intensieve bloeddrukverlaging na trombectomie bij CVA is schadelijk","published":"2022-11-05","doi":"10.1016/S0140-6736(22)01882-7","journal":"Lancet (London, England)","significance":9}]},{"trial":"EPIC-HIV","count":1,"first_published":"2026-04-06","last_published":"2026-04-06","articles":[{"url":"https://hartvaat.nl/2026/02/28/epic-hiv-trial-pcsk9-remming-ter-cardiovasculaire-preventie-bij-hiv-patienten/","title":"EPIC-HIV trial: PCSK9-remming ter cardiovasculaire preventie bij hiv-patiënten","published":"2026-04-06","doi":"10.1016/j.ahj.2026.107400","journal":"American heart journal","significance":5}]},{"trial":"EVOLUTION-HF CEE-BA","count":1,"first_published":"2026-03-20","last_published":"2026-03-20","articles":[{"url":"https://hartvaat.nl/2026/03/20/evolution-hf-cee-ba-real-world-dapagliflozin-bij-hfref-in-centraal-en-oost-europ/","title":"EVOLUTION-HF CEE-BA: real-world dapagliflozin bij HFrEF in Centraal- en Oost-Europa","published":"2026-03-20","doi":"10.1093/eschf/xvag085","journal":"ESC heart failure","significance":6}]},{"trial":"EVOLVED","count":1,"first_published":"2025-01-21","last_published":"2025-01-21","articles":[{"url":"https://hartvaat.nl/2025/01/21/evolved-vroege-interventie-bij-asymptomatische-ernstige-aortastenose-met-myocard/","title":"EVOLVED: vroege interventie bij asymptomatische ernstige aortastenose met myocardfibrose","published":"2025-01-21","doi":"10.1001/jama.2024.22730","journal":"JAMA","significance":9}]},{"trial":"EXPANDed","count":1,"first_published":"2026-06-26","last_published":"2026-06-26","articles":[{"url":"https://hartvaat.nl/2026/05/05/expanded-bij-73-verbetert-tricuspidalisinsufficientie-binnen-30-dagen-na-m-teer-/","title":"EXPANDed: bij 73% verbetert tricuspidalisinsufficiëntie binnen 30 dagen na M-TEER — zonder directe TR-interventie","published":"2026-06-26","doi":"10.1093/eschf/xvag108","journal":"ESC heart failure","significance":7}]},{"trial":"Ez-PAVE","count":1,"first_published":"2026-03-28","last_published":"2026-03-28","articles":[{"url":"https://hartvaat.nl/2026/03/28/ez-pave-ldl-streefwaarde-55-mg-dl-superieur-aan-70-mg-dl-bij-patienten-met-ather/","title":"Ez-PAVE: LDL-streefwaarde <55 mg/dL superieur aan <70 mg/dL bij patiënten met atherosclerotisch vaatlijden","published":"2026-03-28","doi":"https://www.nejm.org/doi/full/10.1056/NEJMoa2600757","journal":"The New England Journal of Medicine","significance":10}]},{"trial":"FAIR-HF2","count":1,"first_published":"2025-06-10","last_published":"2025-06-10","articles":[{"url":"https://hartvaat.nl/2025/06/10/fair-hf2-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-definitieve-r/","title":"FAIR-HF2: IV ferricarboxymaltose bij hartfalen met ijzerdeficiëntie — definitieve RCT","published":"2025-06-10","doi":"10.1001/jama.2025.3833","journal":"JAMA","significance":10}]},{"trial":"FAVOR III","count":1,"first_published":"2022-11-29","last_published":"2022-11-29","articles":[{"url":"https://hartvaat.nl/2022/11/29/favor-iii-qfr-geleide-pci-verbetert-tweejaarsuitkomsten/","title":"FAVOR III: QFR-geleide PCI verbetert tweejaarsuitkomsten","published":"2022-11-29","doi":"10.1016/j.jacc.2022.09.007","journal":"Journal of the American College of Cardiology","significance":7}]},{"trial":"FAVOR IV-QVAS","count":1,"first_published":"2024-11-09","last_published":"2024-11-09","articles":[{"url":"https://hartvaat.nl/2024/11/09/favor-iv-qvas-qfr-versus-ffr-bij-coronaire-revascularisatiedecisies-lancet/","title":"FAVOR IV-QVAS: QFR versus FFR bij coronaire revascularisatiedecisies — Lancet","published":"2024-11-09","doi":"10.1016/S0140-6736(24)02175-5","journal":"Lancet (London, England)","significance":8}]},{"trial":"FINE-HEART","count":1,"first_published":"2026-04-18","last_published":"2026-04-18","articles":[{"url":"https://hartvaat.nl/2026/03/26/fine-heart-vrouwen-met-cardiovasculair-renaal-metabool-syndroom-worden-systemati/","title":"FINE-HEART: vrouwen met cardiovasculair-renaal-metabool syndroom worden systematisch onderbehandeld","published":"2026-04-18","doi":"10.1093/eurheartj/ehag162","journal":"European heart journal","significance":8}]},{"trial":"FINGER","count":1,"first_published":"2022-06-01","last_published":"2022-06-01","articles":[{"url":"https://hartvaat.nl/2022/06/01/finger-trial-multidomein-leefstijlinterventie-verlaagt-cardiovasculair-risico-bi/","title":"FINGER-trial: multidomein-leefstijlinterventie verlaagt cardiovasculair risico bij ouderen","published":"2022-06-01","doi":"10.1093/eurheartj/ehab922","journal":"European heart journal","significance":7}]},{"trial":"FIRE","count":1,"first_published":"2023-09-07","last_published":"2023-09-07","articles":[{"url":"https://hartvaat.nl/2023/09/07/fire-complete-revascularisatie-bij-ouderen-75-jaar-met-mi-nejm/","title":"FIRE: complete revascularisatie bij ouderen ≥75 jaar met MI — NEJM","published":"2023-09-07","doi":"10.1056/NEJMoa2300468","journal":"The New England journal of medicine","significance":9}]},{"trial":"FIRSTMAPPP","count":1,"first_published":"2024-03-16","last_published":"2024-03-16","articles":[{"url":"https://hartvaat.nl/2024/03/16/firstmappp-sunitinib-bij-metastatische-feochromocytomen-en-paragangliomen/","title":"FIRSTMAPPP: sunitinib bij metastatische feochromocytomen en paragangliomen","published":"2024-03-16","doi":"10.1016/S0140-6736(23)02554-0","journal":"Lancet (London, England)","significance":6}]},{"trial":"FLAVOUR","count":1,"first_published":"2022-09-01","last_published":"2022-09-01","articles":[{"url":"https://hartvaat.nl/2022/09/01/flavour-ffr-versus-ivus-voor-pci-beslissingen-bij-coronairlijden/","title":"FLAVOUR: FFR versus IVUS voor PCI-beslissingen bij coronairlijden","published":"2022-09-01","doi":"10.1056/NEJMoa2201546","journal":"The New England journal of medicine","significance":9}]},{"trial":"FRAME-AMI","count":1,"first_published":"2024-04-25","last_published":"2024-04-25","articles":[{"url":"https://hartvaat.nl/2024/04/25/frame-ami-ffr-geleide-versus-complete-pci-bij-mi-nejm/","title":"FRAME-AMI: FFR-geleide versus complete PCI bij MI — NEJM","published":"2024-04-25","doi":"10.1056/NEJMoa2314149","journal":"The New England journal of medicine","significance":9}]},{"trial":"HEART-FID","count":1,"first_published":"2023-09-14","last_published":"2023-09-14","articles":[{"url":"https://hartvaat.nl/2023/09/14/heart-fid-iv-ferricarboxymaltose-bij-hartfalen-met-ijzerdeficientie-nejm/","title":"HEART-FID: IV ferricarboxymaltose bij hartfalen met ijzerdeficiëntie — NEJM","published":"2023-09-14","doi":"10.1056/NEJMoa2304968","journal":"The New England journal of medicine","significance":9}]},{"trial":"HELP-MI","count":1,"first_published":"2025-10-07","last_published":"2025-10-07","articles":[{"url":"https://hartvaat.nl/2025/10/07/help-mi-helicobacter-pylori-screening-na-acuut-mi-cluster-rct/","title":"HELP-MI: Helicobacter pylori-screening na acuut MI — cluster-RCT","published":"2025-10-07","doi":"10.1001/jama.2025.15047","journal":"JAMA","significance":7}]},{"trial":"HEPARIN-STEMI","count":1,"first_published":"2026-04-22","last_published":"2026-04-22","articles":[{"url":"https://hartvaat.nl/2026/03/30/heparin-stemi-prehospitale-heparine-vergroot-vroege-doorstroming-bij-stemi-zonde/","title":"HEPARIN-STEMI: prehospitale heparine vergroot vroege doorstroming bij STEMI zonder meer bloedingen","published":"2026-04-22","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.079839","journal":"Circulation","significance":9}]},{"trial":"HF-REVERT","count":1,"first_published":"2026-05-10","last_published":"2026-05-10","articles":[{"url":"https://hartvaat.nl/2026/05/10/hf-revert-antisense-mirna-remmer-cdr132l-mist-primair-eindpunt-na-infarct-met-ve/","title":"HF-REVERT: antisense miRNA-remmer CDR132L mist primair eindpunt na infarct met verminderde EF","published":"2026-05-10","doi":"10.1038/s41591-026-04408-4","journal":"Nature Medicine","significance":8}]},{"trial":"HI-PEITHO","count":1,"first_published":"2026-03-29","last_published":"2026-03-29","articles":[{"url":"https://hartvaat.nl/2026/03/28/hi-peitho-katheter-gestuurde-trombolyse-halveert-ernstige-uitkomsten-bij-interme/","title":"HI-PEITHO: katheter-gestuurde trombolyse halveert ernstige uitkomsten bij intermediair-hoog-risico longembolie","published":"2026-03-29","doi":"https://www.nejm.org/doi/full/10.1056/NEJMoa2516567&rss=currentIssue","journal":"NEJM","significance":10}]},{"trial":"HOST-REDUCE","count":1,"first_published":"2025-11-08","last_published":"2025-11-08","articles":[{"url":"https://hartvaat.nl/2025/11/08/host-reduce-dapt-na-pci-naar-bloedingsrisico/","title":"HOST-REDUCE: DAPT na PCI naar bloedingsrisico","published":"2025-11-08","doi":"10.1016/S0140-6736(25)01571-5","journal":"Lancet (London, England)","significance":7}]},{"trial":"HuMAIN-HFpEF","count":1,"first_published":"2025-06-01","last_published":"2025-06-01","articles":[{"url":"https://hartvaat.nl/2025/06/01/humain-hfpef-nieuwe-metabole-accelerator-bij-obesitas-hfpef-rct/","title":"HuMAIN-HFpEF: nieuwe metabole accelerator bij obesitas-HFpEF — RCT","published":"2025-06-01","doi":"10.1001/jamacardio.2025.0103","journal":"JAMA cardiology","significance":7}]},{"trial":"IMPROVE-DiCE","count":1,"first_published":"2025-12-18","last_published":"2025-12-18","articles":[{"url":"https://hartvaat.nl/2025/12/18/improve-dice-veiligheid-en-werkzaamheid-van-ninerafaxstat-bij-cardiometabole-syn/","title":"IMPROVE-DiCE: veiligheid en werkzaamheid van ninerafaxstat bij cardiometabole syndromen","published":"2025-12-18","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074041","journal":"Circulation","significance":8}]},{"trial":"INTE-AFRICA","count":1,"first_published":"2023-10-07","last_published":"2023-10-07","articles":[{"url":"https://hartvaat.nl/2023/10/07/inte-africa-geintegreerd-management-van-hiv-diabetes-en-hypertensie-lancet/","title":"INTE-AFRICA: geïntegreerd management van HIV, diabetes en hypertensie — Lancet","published":"2023-10-07","doi":"10.1016/S0140-6736(23)01573-8","journal":"Lancet (London, England)","significance":7}]},{"trial":"INTE-AFRICA 2","count":1,"first_published":"2026-03-14","last_published":"2026-03-14","articles":[{"url":"https://hartvaat.nl/2026/03/14/inte-africa-2-community-based-versus-facilitair-beheer-hiv-dm-htn/","title":"INTE-AFRICA 2: community-based versus facilitair beheer HIV/DM/HTN","published":"2026-03-14","doi":"10.1016/S0140-6736(25)02641-8","journal":"Lancet (London, England)","significance":5}]},{"trial":"INTERACT3","count":1,"first_published":"2023-07-01","last_published":"2023-07-01","articles":[{"url":"https://hartvaat.nl/2023/07/01/interact3-bundeled-care-bij-acute-intracerebrale-bloeding-lancet/","title":"INTERACT3: bundeled care bij acute intracerebrale bloeding — Lancet","published":"2023-07-01","doi":"10.1016/S0140-6736(23)00806-1","journal":"Lancet (London, England)","significance":8}]},{"trial":"INVESTED","count":1,"first_published":"2024-06-01","last_published":"2024-06-01","articles":[{"url":"https://hartvaat.nl/2024/06/01/invested-griepvaccin-immuunrespons-bij-hoog-risico-cv-patienten/","title":"INVESTED: griepvaccin immuunrespons bij hoog-risico CV-patiënten","published":"2024-06-01","doi":"10.1001/jamacardio.2024.0468","journal":"JAMA cardiology","significance":5}]},{"trial":"INVICTUS","count":1,"first_published":"2022-09-15","last_published":"2022-09-15","articles":[{"url":"https://hartvaat.nl/2022/09/15/invictus-rivaroxaban-versus-warfarine-bij-reumatische-hartziekte-en-af/","title":"INVICTUS: rivaroxaban versus warfarine bij reumatische hartziekte en AF","published":"2022-09-15","doi":"10.1056/NEJMoa2209051","journal":"The New England journal of medicine","significance":10}]},{"trial":"IVUS-ACS","count":1,"first_published":"2024-05-11","last_published":"2024-05-11","articles":[{"url":"https://hartvaat.nl/2024/05/11/ivus-acs-ivus-geleide-pci-bij-acs-superieur-lancet/","title":"IVUS-ACS: IVUS-geleide PCI bij ACS superieur — Lancet","published":"2024-05-11","doi":"10.1016/S0140-6736(24)00282-4","journal":"Lancet (London, England)","significance":9}]},{"trial":"JAMAC","count":1,"first_published":"2026-02-02","last_published":"2026-02-02","articles":[{"url":"https://hartvaat.nl/2026/02/02/jamac-studie-slechte-5-jaarsprognose-bij-mitralisstenose-door-mitralisringverkal/","title":"JAMAC-studie: slechte 5-jaarsprognose bij mitralisstenose door mitralisringverkalking","published":"2026-02-02","doi":"10.1016/j.jacc.2025.12.004","journal":"Journal of the American College of Cardiology","significance":7}]},{"trial":"KARDIA-2","count":1,"first_published":"2025-07-01","last_published":"2025-07-01","articles":[{"url":"https://hartvaat.nl/2025/07/01/kardia-2-zilebesiran-als-toevoeging-bij-ongecontroleerde-hypertensie-rct/","title":"KARDIA-2: zilebesiran als toevoeging bij ongecontroleerde hypertensie — RCT","published":"2025-07-01","doi":"10.1001/jama.2025.6681","journal":"JAMA","significance":9}]},{"trial":"KARDINAL","count":1,"first_published":"2026-03-28","last_published":"2026-03-28","articles":[{"url":"https://hartvaat.nl/2026/03/28/kardinal-tonlamarsen-verlaagt-angiotensinogeen-maar-laat-geen-significant-bloedd/","title":"KARDINAL: tonlamarsen verlaagt angiotensinogeen maar laat geen significant bloeddrukeffect zien","published":"2026-03-28","doi":"https://www.jacc.org/doi/10.1016/j.jacc.2026.03.001","journal":"Journal of the American College of Cardiology","significance":7}]},{"trial":"KOUNO-TORI","count":1,"first_published":"2026-03-06","last_published":"2026-03-06","articles":[{"url":"https://hartvaat.nl/2026/03/06/kouno-tori-antitrombine-verlengt-de-zwangerschap-niet-bij-vroege-ernstige-pre-ec/","title":"KOUNO-TORI: antitrombine verlengt de zwangerschap niet bij vroege ernstige pre-eclampsie en geeft meer bloedingen","published":"2026-03-06","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.25431","journal":"Hypertension","significance":5}]},{"trial":"KP CHEMO","count":1,"first_published":"2026-07-02","last_published":"2026-07-02","articles":[{"url":"https://hartvaat.nl/2026/04/30/kp-chemo-cumulatieve-incidentie-cancer-therapy-related-cardiac-dysfunction-8-4-h/","title":"KP CHEMO: cumulatieve incidentie cancer-therapy-related cardiac dysfunction 8,4% — hoogste bij HER2-remmers","published":"2026-07-02","doi":"10.1093/eschf/xvag113","journal":"ESC heart failure","significance":8}]},{"trial":"LAAOS III","count":1,"first_published":"2023-10-24","last_published":"2023-10-24","articles":[{"url":"https://hartvaat.nl/2023/10/24/laaos-iii-laa-occlusie-en-anticoagulatiegebruik/","title":"LAAOS III: LAA-occlusie en anticoagulatiegebruik","published":"2023-10-24","doi":"10.1161/CIRCULATIONAHA.122.060315","journal":"Circulation","significance":7}]},{"trial":"LEAF","count":1,"first_published":"2026-03-30","last_published":"2026-03-30","articles":[{"url":"https://hartvaat.nl/2026/03/30/leaf-liraglutide-voor-ablatie-verbetert-af-vrije-overleving/","title":"LEAF: liraglutide vóór ablatie verbetert AF-vrije overleving","published":"2026-03-30","doi":"10.1016/j.jacep.2026.03.026","journal":"JACC. Clinical electrophysiology","significance":7}]},{"trial":"LEFT-BUNDLE-CRT","count":1,"first_published":"2026-07-14","last_published":"2026-07-14","articles":[{"url":"https://hartvaat.nl/2026/04/14/left-bundle-crt-linkerbundeltak-pacing-niet-aantoonbaar-non-inferieur-aan-bivent/","title":"LEFT-BUNDLE-CRT: linkerbundeltak-pacing niet aantoonbaar non-inferieur aan biventriculaire CRT","published":"2026-07-14","doi":"10.1093/eurheartj/ehag225","journal":"European heart journal","significance":7}]},{"trial":"LEVOECMO","count":1,"first_published":"2026-01-06","last_published":"2026-01-06","articles":[{"url":"https://hartvaat.nl/2026/01/06/levoecmo-levosimendan-bij-ecmo-weaning-bij-cardiogene-shock/","title":"LEVOECMO: levosimendan bij ECMO-weaning bij cardiogene shock","published":"2026-01-06","doi":"10.1001/jama.2025.19843","journal":"JAMA","significance":7}]},{"trial":"LINEAR","count":1,"first_published":"2026-04-19","last_published":"2026-04-19","articles":[{"url":"https://hartvaat.nl/2026/03/30/linear-trial-lattice-tip-katheter-verslaat-standaard-irrigatie-bij-cti-ablatie-v/","title":"LINEAR-trial: lattice-tip-katheter verslaat standaard irrigatie bij CTI-ablatie voor typische atriumflutter","published":"2026-04-19","doi":"10.1093/europace/euag046","journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","significance":7}]},{"trial":"LODESTAR","count":1,"first_published":"2023-04-04","last_published":"2023-04-04","articles":[{"url":"https://hartvaat.nl/2023/04/04/lodestar-treat-to-target-versus-hoge-dosis-statine-bij-coronairlijden/","title":"LODESTAR: treat-to-target versus hoge-dosis statine bij coronairlijden","published":"2023-04-04","doi":"10.1001/jama.2023.2487","journal":"JAMA","significance":8}]},{"trial":"Look AHEAD","count":1,"first_published":"2025-02-11","last_published":"2025-02-11","articles":[{"url":"https://hartvaat.nl/2025/02/11/look-ahead-intensieve-leefstijlinterventie-cardiale-biomarkers-en-cv-uitkomsten-/","title":"Look AHEAD: intensieve leefstijlinterventie, cardiale biomarkers en CV-uitkomsten bij diabetes","published":"2025-02-11","doi":"10.1016/j.jacc.2024.11.004","journal":"Journal of the American College of Cardiology","significance":7}]},{"trial":"MAPLE-HCM","count":1,"first_published":"2026-03-18","last_published":"2026-03-18","articles":[{"url":"https://hartvaat.nl/2025/01/01/maple-hcm-is-aficamten-een-keerpunt-bij-obstructieve-hcm/","title":"MAPLE-HCM: is aficamten een keerpunt bij obstructieve HCM?","published":"2026-03-18","doi":"https://www.sciencedirect.com/science/article/pii/S0735109725103598?dgcid=rss_sd_all","journal":"JACC","significance":7}]},{"trial":"MASTER DAPT","count":1,"first_published":"2025-08-19","last_published":"2025-08-19","articles":[{"url":"https://hartvaat.nl/2025/08/19/master-dapt-recurrente-events-analyse-van-verkorte-versus-standaard-dapt/","title":"MASTER DAPT: recurrente events analyse van verkorte versus standaard DAPT","published":"2025-08-19","doi":"10.1016/j.jacc.2025.05.010","journal":"Journal of the American College of Cardiology","significance":6}]},{"trial":"MATTERHORN","count":1,"first_published":"2024-11-14","last_published":"2024-11-14","articles":[{"url":"https://hartvaat.nl/2024/11/14/matterhorn-transcatheter-repair-versus-chirurgie-bij-secundaire-mr-nejm/","title":"MATTERHORN: transcatheter repair versus chirurgie bij secundaire MR — NEJM","published":"2024-11-14","doi":"10.1056/NEJMoa2408739","journal":"The New England journal of medicine","significance":9}]},{"trial":"MESSAGE-HF","count":1,"first_published":"2024-02-01","last_published":"2024-02-01","articles":[{"url":"https://hartvaat.nl/2024/02/01/message-hf-geautomatiseerde-sms-na-hartfalenopname-verbetert-uitkomsten-niet/","title":"MESSAGE-HF: geautomatiseerde sms na hartfalenopname verbetert uitkomsten niet","published":"2024-02-01","doi":"10.1001/jamacardio.2023.4501","journal":"JAMA cardiology","significance":6}]},{"trial":"METEORIC-HF","count":1,"first_published":"2022-07-19","last_published":"2022-07-19","articles":[{"url":"https://hartvaat.nl/2022/07/19/meteoric-hf-omecamtiv-mecarbil-verbetert-inspanningscapaciteit-niet-bij-hfref/","title":"METEORIC-HF: omecamtiv mecarbil verbetert inspanningscapaciteit niet bij HFrEF","published":"2022-07-19","doi":"10.1001/jama.2022.11016","journal":"JAMA","significance":8}]},{"trial":"MK-0616","count":1,"first_published":"2023-04-25","last_published":"2023-04-25","articles":[{"url":"https://hartvaat.nl/2023/04/25/mk-0616-eerste-orale-pcsk9-remmer-in-fase-2b/","title":"MK-0616: eerste orale PCSK9-remmer in fase 2b","published":"2023-04-25","doi":"10.1016/j.jacc.2023.02.018","journal":"Journal of the American College of Cardiology","significance":9}]},{"trial":"MOMENTUM 3","count":1,"first_published":"2022-09-27","last_published":"2022-09-27","articles":[{"url":"https://hartvaat.nl/2022/09/27/momentum-3-vijfjaarsresultaten-heartmate-3-versus-axiale-lvad/","title":"MOMENTUM 3: vijfjaarsresultaten HeartMate 3 versus axiale LVAD","published":"2022-09-27","doi":"10.1001/jama.2022.16197","journal":"JAMA","significance":9}]},{"trial":"MONITOR-HF","count":1,"first_published":"2023-06-24","last_published":"2023-06-24","articles":[{"url":"https://hartvaat.nl/2023/06/24/monitor-hf-pa-drukmonitoring-bij-hartfalen-effectief-in-europa-lancet-rct/","title":"MONITOR-HF: PA-drukmonitoring bij hartfalen effectief in Europa — Lancet RCT","published":"2023-06-24","doi":"10.1016/S0140-6736(23)00923-6","journal":"Lancet (London, England)","significance":9}]},{"trial":"MORE-CRT MPP","count":1,"first_published":"2023-10-05","last_published":"2023-10-05","articles":[{"url":"https://hartvaat.nl/2023/10/05/more-crt-mpp-multipoint-pacing-bij-crt-non-responders/","title":"MORE-CRT MPP: multipoint pacing bij CRT non-responders","published":"2023-10-05","doi":"10.1093/europace/euad294","journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","significance":6}]},{"trial":"MULTISTARS AMI","count":1,"first_published":"2023-10-12","last_published":"2023-10-12","articles":[{"url":"https://hartvaat.nl/2023/10/12/multistars-ami-timing-van-complete-revascularisatie-bij-stemi-nejm/","title":"MULTISTARS AMI: timing van complete revascularisatie bij STEMI — NEJM","published":"2023-10-12","doi":"10.1056/NEJMoa2307823","journal":"The New England journal of medicine","significance":9}]},{"trial":"NEO-MINOR","count":1,"first_published":"2026-01-27","last_published":"2026-01-27","articles":[{"url":"https://hartvaat.nl/2026/01/27/neo-minor-potente-p2y12-monotherapie-versus-dapt-na-pci-bij-stemi/","title":"NEO-MINOR: potente P2Y12-monotherapie versus DAPT na PCI bij STEMI","published":"2026-01-27","doi":"10.1016/j.jacc.2025.10.058","journal":"Journal of the American College of Cardiology","significance":8}]},{"trial":"NEWTON-CABG","count":1,"first_published":"2025-09-20","last_published":"2025-09-20","articles":[{"url":"https://hartvaat.nl/2025/09/20/newton-cabg-evolocumab-en-veneuze-graftpatency-na-cabg/","title":"NEWTON-CABG: evolocumab en veneuze graftpatency na CABG","published":"2025-09-20","doi":"10.1016/S0140-6736(25)01633-2","journal":"Lancet (London, England)","significance":8}]},{"trial":"NI006","count":1,"first_published":"2023-07-20","last_published":"2023-07-20","articles":[{"url":"https://hartvaat.nl/2023/07/20/ni006-antilichaam-voor-afbraak-van-cardiale-transthyretine-amyloid-nejm-fase-1/","title":"NI006: antilichaam voor afbraak van cardiale transthyretine-amyloid — NEJM fase 1","published":"2023-07-20","doi":"10.1056/NEJMoa2303765","journal":"The New England journal of medicine","significance":9}]},{"trial":"NITRATE-CIN","count":1,"first_published":"2024-05-13","last_published":"2024-05-13","articles":[{"url":"https://hartvaat.nl/2024/05/13/nitrate-cin-nitraat-beschermt-tegen-contrastnefropathie-na-acs/","title":"NITRATE-CIN: nitraat beschermt tegen contrastnefropathie na ACS","published":"2024-05-13","doi":"10.1093/eurheartj/ehae100","journal":"European heart journal","significance":7}]},{"trial":"NOAH-AFNET 6","count":1,"first_published":"2023-09-28","last_published":"2023-09-28","articles":[{"url":"https://hartvaat.nl/2023/09/28/noah-afnet-6-edoxaban-bij-atriaal-high-rate-episodes-nejm/","title":"NOAH-AFNET 6: edoxaban bij atriaal high-rate episodes — NEJM","published":"2023-09-28","doi":"10.1056/NEJMoa2303062","journal":"The New England journal of medicine","significance":10}]},{"trial":"NUDGE-FLU","count":1,"first_published":"2024-05-27","last_published":"2024-05-27","articles":[{"url":"https://hartvaat.nl/2024/05/27/nudge-flu-elektronische-nudges-verhogen-griepvaccinatie-na-mi/","title":"NUDGE-FLU: elektronische nudges verhogen griepvaccinatie na MI","published":"2024-05-27","doi":"10.1093/eurheartj/ehae235","journal":"European heart journal","significance":6}]},{"trial":"OCCUPI","count":1,"first_published":"2026-02-09","last_published":"2026-02-09","articles":[{"url":"https://hartvaat.nl/2026/02/09/occupi-oct-geleide-stentoptimalisatie-bij-complexe-coronairlaesies/","title":"OCCUPI: OCT-geleide stentoptimalisatie bij complexe coronairlaesies","published":"2026-02-09","doi":"10.1093/eurheartj/ehaf884","journal":"European heart journal","significance":7}]},{"trial":"OCTIVUS","count":1,"first_published":"2023-10-17","last_published":"2023-10-17","articles":[{"url":"https://hartvaat.nl/2023/10/17/octivus-oct-geleide-versus-ivus-geleide-pci-non-inferioriteit-bevestigd/","title":"OCTIVUS: OCT-geleide versus IVUS-geleide PCI — non-inferioriteit bevestigd","published":"2023-10-17","doi":"10.1161/CIRCULATIONAHA.123.066429","journal":"Circulation","significance":8}]},{"trial":"OCTOBER","count":1,"first_published":"2023-10-19","last_published":"2023-10-19","articles":[{"url":"https://hartvaat.nl/2023/10/19/october-oct-geleide-pci-bij-complexe-bifurcatielaesies-nejm/","title":"OCTOBER: OCT-geleide PCI bij complexe bifurcatielaesies — NEJM","published":"2023-10-19","doi":"10.1056/NEJMoa2307770","journal":"The New England journal of medicine","significance":9}]},{"trial":"OPT-BIRISK","count":1,"first_published":"2024-06-01","last_published":"2024-06-01","articles":[{"url":"https://hartvaat.nl/2024/06/01/opt-birisk-clopidogrel-monotherapie-bij-acs-met-hoog-ischemisch-en-bloedingsrisi/","title":"OPT-BIRISK: clopidogrel monotherapie bij ACS met hoog ischemisch én bloedingsrisico","published":"2024-06-01","doi":"10.1001/jamacardio.2024.0534","journal":"JAMA cardiology","significance":7}]},{"trial":"OPTIMAL-BP","count":1,"first_published":"2023-09-05","last_published":"2023-09-05","articles":[{"url":"https://hartvaat.nl/2023/09/05/optimal-bp-intensieve-bloeddrukverlaging-na-trombectomie-bij-cva-jama/","title":"OPTIMAL-BP: intensieve bloeddrukverlaging na trombectomie bij CVA — JAMA","published":"2023-09-05","doi":"10.1001/jama.2023.14590","journal":"JAMA","significance":7}]},{"trial":"OPTION","count":1,"first_published":"2023-01-17","last_published":"2023-01-17","articles":[{"url":"https://hartvaat.nl/2023/01/17/option-indobufen-als-aspirine-alternatief-in-dapt-na-pci/","title":"OPTION: indobufen als aspirine-alternatief in DAPT na PCI","published":"2023-01-17","doi":"10.1161/CIRCULATIONAHA.122.062762","journal":"Circulation","significance":6}]},{"trial":"ORBITA-COSMIC","count":1,"first_published":"2024-04-20","last_published":"2024-04-20","articles":[{"url":"https://hartvaat.nl/2024/04/20/orbita-cosmic-coronaire-sinusreducer-bij-refractaire-angina-sham-gecontroleerd/","title":"ORBITA-COSMIC: coronaire sinusreducer bij refractaire angina — sham-gecontroleerd","published":"2024-04-20","doi":"10.1016/S0140-6736(24)00256-3","journal":"Lancet (London, England)","significance":7}]},{"trial":"ORBITA-FIRE","count":1,"first_published":"2026-07-09","last_published":"2026-07-09","articles":[{"url":"https://hartvaat.nl/2026/05/08/orbita-fire-fysiologische-angina-drempel-ligt-veel-lager-dan-klinische-ffr-grens/","title":"ORBITA-FIRE: fysiologische angina-drempel ligt veel lager dan klinische FFR-grens — pleidooi voor individuele revascularisatie-strategie","published":"2026-07-09","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.078738","journal":"Circulation","significance":8}]},{"trial":"ORION-11","count":1,"first_published":"2022-12-21","last_published":"2022-12-21","articles":[{"url":"https://hartvaat.nl/2022/12/21/orion-11-inclisiran-verlaagt-ldl-effectief-bij-primaire-preventie/","title":"ORION-11: inclisiran verlaagt LDL effectief bij primaire preventie","published":"2022-12-21","doi":"10.1093/eurheartj/ehac615","journal":"European heart journal","significance":7}]},{"trial":"ORION-5","count":1,"first_published":"2024-01-30","last_published":"2024-01-30","articles":[{"url":"https://hartvaat.nl/2024/01/30/orion-5-inclisiran-bij-homozygote-fh/","title":"ORION-5: inclisiran bij homozygote FH","published":"2024-01-30","doi":"10.1161/CIRCULATIONAHA.122.063460","journal":"Circulation","significance":7}]},{"trial":"PAM-VT 2","count":1,"first_published":"2026-03-25","last_published":"2026-03-25","articles":[{"url":"https://hartvaat.nl/2026/03/02/pam-vt-2-littekenverloop-na-vt-ablatie-beoordeeld-met-seriele-cardiale-mri/","title":"PAM-VT 2: littekenverloop na VT-ablatie beoordeeld met seriële cardiale MRI","published":"2026-03-25","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.074748","journal":"Circulation","significance":6}]},{"trial":"PANDA II","count":1,"first_published":"2025-09-06","last_published":"2025-09-06","articles":[{"url":"https://hartvaat.nl/2025/09/06/panda-ii-griepvaccinatie-bij-acuut-hartfalen-multicenter-rct/","title":"PANDA II: griepvaccinatie bij acuut hartfalen — multicenter RCT","published":"2025-09-06","doi":"10.1016/S0140-6736(25)01485-0","journal":"Lancet (London, England)","significance":6}]},{"trial":"PANORAMA-HF","count":1,"first_published":"2024-11-26","last_published":"2024-11-26","articles":[{"url":"https://hartvaat.nl/2024/11/26/panorama-hf-sacubitril-valsartan-bij-pediatrisch-hartfalen-nejm/","title":"PANORAMA-HF: sacubitril/valsartan bij pediatrisch hartfalen — NEJM","published":"2024-11-26","doi":"10.1161/CIRCULATIONAHA.123.066605","journal":"Circulation","significance":7}]},{"trial":"PARABLE","count":1,"first_published":"2023-04-01","last_published":"2023-04-01","articles":[{"url":"https://hartvaat.nl/2023/04/01/parable-sacubitril-valsartan-vermindert-linkeratriumvolume-bij-pre-hfpef/","title":"PARABLE: sacubitril/valsartan vermindert linkeratriumvolume bij pre-HFpEF","published":"2023-04-01","doi":"10.1001/jamacardio.2023.0065","journal":"JAMA cardiology","significance":7}]},{"trial":"PARADISE","count":1,"first_published":"2026-05-11","last_published":"2026-05-11","articles":[{"url":"https://hartvaat.nl/2026/05/10/paradise-gelijktijdig-acuut-hartfalen-plus-luchtweginfectie-verhoogt-sterfte-tij/","title":"PARADISE: gelijktijdig acuut hartfalen plus luchtweginfectie verhoogt sterfte tijdens opname, niet daarna","published":"2026-05-11","doi":"10.1093/ejhf/xuag160","journal":"European Journal of Heart Failure","significance":7}]},{"trial":"PARTNER 3","count":1,"first_published":"2026-02-19","last_published":"2026-02-19","articles":[{"url":"https://hartvaat.nl/2026/02/19/partner-3-tavr-versus-chirurgie-bij-laagrisico-zevenjaarsresultaten-nejm/","title":"PARTNER 3: TAVR versus chirurgie bij laagrisico — zevenjaarsresultaten NEJM","published":"2026-02-19","doi":"10.1056/NEJMoa2509766","journal":"The New England journal of medicine","significance":9}]},{"trial":"PATHFINDER","count":1,"first_published":"2026-02-23","last_published":"2026-02-23","articles":[{"url":"https://hartvaat.nl/2026/02/23/pathfinder-trial-betere-naleving-van-hartfalenrichtlijnen-in-de-huisartsenprakti/","title":"PATHFINDER-trial: betere naleving van hartfalenrichtlijnen in de huisartsenpraktijk","published":"2026-02-23","doi":"10.1093/eschf/xvag061","journal":"ESC heart failure","significance":6}]},{"trial":"PFA-SHAM","count":1,"first_published":"2026-07-02","last_published":"2026-07-02","articles":[{"url":"https://hartvaat.nl/2026/05/26/pfa-sham-pulsed-field-ablatie-verslaat-sham-procedure-overtuigend-bij-atriumfibr/","title":"PFA-SHAM: pulsed field-ablatie verslaat sham-procedure overtuigend bij atriumfibrilleren — placebo-effect uitgesloten","published":"2026-07-02","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.079484","journal":"Circulation","significance":9}]},{"trial":"PHOTON","count":1,"first_published":"2024-03-23","last_published":"2024-03-23","articles":[{"url":"https://hartvaat.nl/2024/03/23/photon-aflibercept-8-mg-bij-diabetisch-macula-oedeem-verlengd-doseerinterval/","title":"PHOTON: aflibercept 8 mg bij diabetisch macula-oedeem — verlengd doseerinterval","published":"2024-03-23","doi":"10.1016/S0140-6736(23)02577-1","journal":"Lancet (London, England)","significance":6}]},{"trial":"PINGS","count":1,"first_published":"2026-07-16","last_published":"2026-07-16","articles":[{"url":"https://hartvaat.nl/2026/04/09/pings-telefonische-verpleegkundig-geleide-bloeddrukcontrole-na-een-beroerte-ghan/","title":"PINGS: telefonische, verpleegkundig geleide bloeddrukcontrole na een beroerte (Ghana)","published":"2026-07-16","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.125.077424","journal":"Circulation","significance":7}]},{"trial":"POET-II","count":1,"first_published":"2026-08-28","last_published":"2026-08-28","articles":[{"url":"https://hartvaat.nl/2026/08/28/poet-ii-responsgestuurde-antibioticaduur-bij-linkszijdige-endocarditis-scheelt-t/","title":"POET-II: responsgestuurde antibioticaduur bij linkszijdige endocarditis scheelt twee weken en is niet-inferieur, maar geeft meer recidieven","published":"2026-08-28","doi":"10.1056/NEJMoa2607887","journal":"New England Journal of Medicine","significance":7}]},{"trial":"PORTHOS","count":1,"first_published":"2026-05-11","last_published":"2026-05-11","articles":[{"url":"https://hartvaat.nl/2026/05/10/porthos-nt-probnp-afkapwaarden-onbetrouwbaar-bij-obese-patienten-risico-op-gemis/","title":"PORTHOS: NT-proBNP-afkapwaarden onbetrouwbaar bij obese patiënten — risico op gemiste hartfalendiagnose","published":"2026-05-11","doi":"10.1093/ejhf/xuag154","journal":"European Journal of Heart Failure","significance":8}]},{"trial":"POSEIDON","count":1,"first_published":"2026-05-11","last_published":"2026-05-11","articles":[{"url":"https://hartvaat.nl/2026/05/10/poseidon-4-op-10-patienten-met-hartfalen-wereldwijd-heeft-inflammatoir-verhoogd-/","title":"POSEIDON: 4 op 10 patiënten met hartfalen wereldwijd heeft inflammatoir verhoogd hsCRP — basis voor anti-inflammatoire therapie","published":"2026-05-11","doi":"10.1093/ejhf/xuag155","journal":"European Journal of Heart Failure","significance":8}]},{"trial":"PRAETORIAN-DFT","count":1,"first_published":"2026-05-09","last_published":"2026-05-09","articles":[{"url":"https://hartvaat.nl/2026/04/25/praetorian-dft-defibrillatietest-bij-subcutane-icd-veilig-achterwege-te-laten/","title":"PRAETORIAN-DFT: defibrillatietest bij subcutane ICD veilig achterwege te laten","published":"2026-05-09","doi":"https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.126.080638","journal":"Circulation","significance":8}]},{"trial":"PRECISE","count":1,"first_published":"2023-10-01","last_published":"2023-10-01","articles":[{"url":"https://hartvaat.nl/2023/10/01/precise-uitgesteld-testen-bij-stabiel-coronairlijden-is-veilig/","title":"PRECISE: uitgesteld testen bij stabiel coronairlijden is veilig","published":"2023-10-01","doi":"10.1001/jamacardio.2023.2614","journal":"JAMA cardiology","significance":7}]},{"trial":"PRECISION","count":1,"first_published":"2022-12-03","last_published":"2022-12-03","articles":[{"url":"https://hartvaat.nl/2022/12/03/precision-aprocitentan-bij-resistente-hypertensie-eerste-endothelineantagonist/","title":"PRECISION: aprocitentan bij resistente hypertensie — eerste endothelineantagonist","published":"2022-12-03","doi":"10.1016/S0140-6736(22)02034-7","journal":"Lancet (London, England)","significance":9}]},{"trial":"PREMIER","count":1,"first_published":"2024-11-08","last_published":"2024-11-08","articles":[{"url":"https://hartvaat.nl/2024/11/08/premier-in-hospital-start-van-sacubitril-valsartan-bij-acuut-hartfalen/","title":"PREMIER: in-hospital start van sacubitril/valsartan bij acuut hartfalen","published":"2024-11-08","doi":"10.1093/eurheartj/ehae561","journal":"European heart journal","significance":7}]},{"trial":"PRINCE","count":1,"first_published":"2025-10-28","last_published":"2025-10-28","articles":[{"url":"https://hartvaat.nl/2025/10/28/prince-remote-ischemische-preconditionering-en-myocardletsel-bij-niet-cardiale-c/","title":"PRINCE: remote ischemische preconditionering en myocardletsel bij niet-cardiale chirurgie","published":"2025-10-28","doi":"10.1161/CIRCULATIONAHA.125.075254","journal":"Circulation","significance":6}]},{"trial":"PRO-HF","count":1,"first_published":"2024-05-28","last_published":"2024-05-28","articles":[{"url":"https://hartvaat.nl/2024/05/28/pro-hf-routine-prom-meting-in-hartfalenpolikliniek-verbetert-uitkomsten/","title":"PRO-HF: routine PROM-meting in hartfalenpolikliniek verbetert uitkomsten","published":"2024-05-28","doi":"10.1161/CIRCULATIONAHA.124.069624","journal":"Circulation","significance":7}]},{"trial":"PROMINENT","count":1,"first_published":"2022-11-24","last_published":"2022-11-24","articles":[{"url":"https://hartvaat.nl/2022/11/24/prominent-pemafibrate-verlaagt-triglyceriden-maar-vermindert-cv-events-niet/","title":"PROMINENT: pemafibrate verlaagt triglyceriden maar vermindert CV-events niet","published":"2022-11-24","doi":"10.1056/NEJMoa2210645","journal":"The New England journal of medicine","significance":10}]},{"trial":"PROMPT-AHF","count":1,"first_published":"2023-10-21","last_published":"2023-10-21","articles":[{"url":"https://hartvaat.nl/2023/10/21/prompt-ahf-epd-alerts-verbeteren-hartfalenmedicatie-bij-ontslag/","title":"PROMPT-AHF: EPD-alerts verbeteren hartfalenmedicatie bij ontslag","published":"2023-10-21","doi":"10.1093/eurheartj/ehad512","journal":"European heart journal","significance":7}]},{"trial":"PROTECCT","count":1,"first_published":"2022-11-24","last_published":"2022-11-24","articles":[{"url":"https://hartvaat.nl/2022/11/24/protecct-ct-bij-verdenking-acs-met-intermediaire-troponinewaarden/","title":"PROTECCT: CT bij verdenking ACS met intermediaire troponinewaarden","published":"2022-11-24","doi":"10.1136/heartjnl-2022-320990","journal":"Heart (British Cardiac Society)","significance":7}]},{"trial":"PULSE-MI","count":1,"first_published":"2024-10-01","last_published":"2024-10-01","articles":[{"url":"https://hartvaat.nl/2024/10/01/pulse-mi-prehospitale-puls-dosis-glucocorticoid-bij-stemi/","title":"PULSE-MI: prehospitale puls-dosis glucocorticoïd bij STEMI","published":"2024-10-01","doi":"10.1001/jamacardio.2024.2298","journal":"JAMA cardiology","significance":6}]},{"trial":"PURSUIT","count":1,"first_published":"2025-06-03","last_published":"2025-06-03","articles":[{"url":"https://hartvaat.nl/2025/06/03/pursuit-orale-pcsk9-remmer-voor-hypercholesterolemie-gerandomiseerde-trial/","title":"PURSUIT: orale PCSK9-remmer voor hypercholesterolemie — gerandomiseerde trial","published":"2025-06-03","doi":"10.1016/j.jacc.2025.03.499","journal":"Journal of the American College of Cardiology","significance":9}]},{"trial":"QDOT-by-LAWT","count":1,"first_published":"2024-03-30","last_published":"2024-03-30","articles":[{"url":"https://hartvaat.nl/2024/03/30/qdot-by-lawt-gepersonaliseerde-pvi-gestuurd-door-linkeratriale-wanddikte/","title":"QDOT-by-LAWT: gepersonaliseerde PVI gestuurd door linkeratriale wanddikte","published":"2024-03-30","doi":"10.1093/europace/euae087","journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","significance":6}]},{"trial":"QUARTET","count":1,"first_published":"2024-05-01","last_published":"2024-05-01","articles":[{"url":"https://hartvaat.nl/2024/05/01/quartet-therapeutische-inertie-bij-lage-dosis-viervoudige-combinatietherapie/","title":"QUARTET: therapeutische inertie bij lage-dosis viervoudige combinatietherapie","published":"2024-05-01","doi":"10.1161/HYPERTENSIONAHA.123.22284","journal":"Hypertension (Dallas, Tex. : 1979)","significance":6}]},{"trial":"RADIANCE II","count":1,"first_published":"2023-02-28","last_published":"2023-02-28","articles":[{"url":"https://hartvaat.nl/2023/02/28/radiance-ii-ultrageluid-renale-denervatie-bij-milde-tot-matige-hypertensie/","title":"RADIANCE II: ultrageluid renale denervatie bij milde tot matige hypertensie","published":"2023-02-28","doi":"10.1001/jama.2023.0713","journal":"JAMA","significance":8}]},{"trial":"RADIANCE-HTN TRIO","count":1,"first_published":"2022-12-01","last_published":"2022-12-01","articles":[{"url":"https://hartvaat.nl/2022/12/01/radiance-htn-trio-renale-denervatie-effectief-na-medicatie-optitratie/","title":"RADIANCE-HTN TRIO: renale denervatie effectief na medicatie-optitratie","published":"2022-12-01","doi":"10.1001/jamacardio.2022.3904","journal":"JAMA cardiology","significance":7}]},{"trial":"RAFT-AF","count":1,"first_published":"2022-06-07","last_published":"2022-06-07","articles":[{"url":"https://hartvaat.nl/2022/06/07/raft-af-ablatie-versus-rate-control-bij-hartfalen-en-atriumfibrilleren/","title":"RAFT-AF: ablatie versus rate control bij hartfalen en atriumfibrilleren","published":"2022-06-07","doi":"10.1161/CIRCULATIONAHA.121.057095","journal":"Circulation","significance":8}]},{"trial":"RAPID NSTEMI","count":1,"first_published":"2024-03-12","last_published":"2024-03-12","articles":[{"url":"https://hartvaat.nl/2024/03/12/rapid-nstemi-zeer-vroege-invasieve-strategie-bij-hoger-risico-nstemi/","title":"RAPID NSTEMI: zeer vroege invasieve strategie bij hoger risico NSTEMI","published":"2024-03-12","doi":"10.1136/heartjnl-2023-323513","journal":"Heart (British Cardiac Society)","significance":6}]},{"trial":"RATE-AF","count":1,"first_published":"2025-03-26","last_published":"2025-03-26","articles":[{"url":"https://hartvaat.nl/2025/03/26/rate-af-kosteneffectiviteit-van-digoxine-versus-betablokkers-bij-permanent-af/","title":"RATE-AF: kosteneffectiviteit van digoxine versus bètablokkers bij permanent AF","published":"2025-03-26","doi":"10.1136/heartjnl-2024-324761","journal":"Heart (British Cardiac Society)","significance":7}]},{"trial":"REALITY","count":1,"first_published":"2023-12-28","last_published":"2023-12-28","articles":[{"url":"https://hartvaat.nl/2023/12/28/reality-restrictief-versus-liberaal-transfusiebeleid-bij-mi-en-anemie-nejm/","title":"REALITY: restrictief versus liberaal transfusiebeleid bij MI en anemie — NEJM","published":"2023-12-28","doi":"10.1056/NEJMoa2307983","journal":"The New England journal of medicine","significance":8}]},{"trial":"REBOOT","count":1,"first_published":"2026-02-11","last_published":"2026-02-11","articles":[{"url":"https://hartvaat.nl/2026/02/11/reboot-betablokkers-na-mi-sekseverschillen/","title":"REBOOT: bètablokkers na MI — sekseverschillen","published":"2026-02-11","doi":"10.1093/eurheartj/ehaf673","journal":"European heart journal","significance":5}]},{"trial":"REC-CAGEFREE","count":1,"first_published":"2026-01-27","last_published":"2026-01-27","articles":[{"url":"https://hartvaat.nl/2026/01/27/rec-cagefree-dcb-versus-stenting-bij-de-novo-cad-driejaarsdata/","title":"REC-CAGEFREE: DCB versus stenting bij de novo CAD — driejaarsdata","published":"2026-01-27","doi":"10.1016/j.jacc.2025.10.027","journal":"Journal of the American College of Cardiology","significance":6}]},{"trial":"REDO-FIRM","count":1,"first_published":"2023-02-08","last_published":"2023-02-08","articles":[{"url":"https://hartvaat.nl/2023/02/08/redo-firm-firm-geleide-ablatie-verbetert-uitkomst-niet-bij-recidief-af/","title":"REDO-FIRM: FIRM-geleide ablatie verbetert uitkomst niet bij recidief-AF","published":"2023-02-08","doi":"10.1093/europace/euac122","journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","significance":6}]},{"trial":"REDUCE LAP-HF II","count":1,"first_published":"2024-06-01","last_published":"2024-06-01","articles":[{"url":"https://hartvaat.nl/2024/06/01/reduce-lap-hf-ii-atriaal-shuntdevice-bij-hfpef-cardiale-effecten/","title":"REDUCE LAP-HF II: atriaal shuntdevice bij HFpEF — cardiale effecten","published":"2024-06-01","doi":"10.1001/jamacardio.2024.0520","journal":"JAMA cardiology","significance":6}]},{"trial":"REDUCE-IT","count":1,"first_published":"2022-08-02","last_published":"2022-08-02","articles":[{"url":"https://hartvaat.nl/2022/08/02/reduce-it-icosapent-ethyl-vermindert-inflammatiemarkers/","title":"REDUCE-IT: icosapent ethyl vermindert inflammatiemarkers","published":"2022-08-02","doi":"10.1161/CIRCULATIONAHA.122.059410","journal":"Circulation","significance":7}]},{"trial":"REDUCE-IT USA","count":1,"first_published":"2020-02-04","last_published":"2020-02-04","articles":[{"url":"https://hartvaat.nl/2020/02/04/reduce-it-usa-resultaten-bij-3-146-amerikaanse-deelnemers/","title":"REDUCE-IT USA: resultaten bij 3.146 Amerikaanse deelnemers","published":"2020-02-04","doi":"10.1161/CIRCULATIONAHA.119.044440","journal":"Circulation","significance":6}]},{"trial":"RELIEVE-HF","count":1,"first_published":"2024-12-10","last_published":"2024-12-10","articles":[{"url":"https://hartvaat.nl/2024/12/10/relieve-hf-interatriale-shunt-bij-hartfalen-negatieve-gerandomiseerde-trial/","title":"RELIEVE-HF: interatriale shunt bij hartfalen — negatieve gerandomiseerde trial","published":"2024-12-10","doi":"10.1161/CIRCULATIONAHA.124.070870","journal":"Circulation","significance":7}]},{"trial":"REPRIEVE","count":1,"first_published":"2023-08-24","last_published":"2023-08-24","articles":[{"url":"https://hartvaat.nl/2023/08/24/reprieve-pitavastatine-vermindert-cv-events-bij-hiv-nejm/","title":"REPRIEVE: pitavastatine vermindert CV-events bij HIV — NEJM","published":"2023-08-24","doi":"10.1056/NEJMoa2304146","journal":"The New England journal of medicine","significance":10}]},{"trial":"RESET-BP","count":1,"first_published":"2024-10-29","last_published":"2024-10-29","articles":[{"url":"https://hartvaat.nl/2024/10/29/reset-bp-minder-sedentair-gedrag-verlaagt-bloeddruk-bij-kantoorwerkers/","title":"RESET-BP: minder sedentair gedrag verlaagt bloeddruk bij kantoorwerkers","published":"2024-10-29","doi":"10.1161/CIRCULATIONAHA.123.068564","journal":"Circulation","significance":6}]},{"trial":"RESHAPE-HF2","count":1,"first_published":"2024-11-14","last_published":"2024-11-14","articles":[{"url":"https://hartvaat.nl/2024/11/14/reshape-hf2-transcatheter-kleprepair-bij-hf-met-matige-tot-ernstige-mr-nejm/","title":"RESHAPE-HF2: transcatheter kleprepair bij HF met matige tot ernstige MR — NEJM","published":"2024-11-14","doi":"10.1056/NEJMoa2314328","journal":"The New England journal of medicine","significance":9}]},{"trial":"REVIVED-BCIS2","count":1,"first_published":"2022-10-13","last_published":"2022-10-13","articles":[{"url":"https://hartvaat.nl/2022/10/13/revived-bcis2-pci-verbetert-overleving-niet-bij-ischemische-lv-disfunctie/","title":"REVIVED-BCIS2: PCI verbetert overleving niet bij ischemische LV-disfunctie","published":"2022-10-13","doi":"10.1056/NEJMoa2206606","journal":"The New England journal of medicine","significance":10}]},{"trial":"RICH LIFE","count":1,"first_published":"2024-07-16","last_published":"2024-07-16","articles":[{"url":"https://hartvaat.nl/2024/07/16/rich-life-gelijkwaardige-hypertensiezorg-voor-achtergestelde-populaties/","title":"RICH LIFE: gelijkwaardige hypertensiezorg voor achtergestelde populaties","published":"2024-07-16","doi":"10.1161/CIRCULATIONAHA.124.069622","journal":"Circulation","significance":7}]},{"trial":"RIGHT-2","count":1,"first_published":"2024-05-30","last_published":"2024-05-30","articles":[{"url":"https://hartvaat.nl/2024/05/30/right-2-ambulancebloeddrukverlaging-bij-hyperacuut-cva-nejm-vervolgresultaten/","title":"RIGHT-2: ambulancebloeddrukverlaging bij hyperacuut CVA — NEJM vervolgresultaten","published":"2024-05-30","doi":"10.1056/NEJMoa2314741","journal":"The New England journal of medicine","significance":8}]},{"trial":"RIPCORD 2","count":1,"first_published":"2022-08-30","last_published":"2022-08-30","articles":[{"url":"https://hartvaat.nl/2022/08/30/ripcord-2-routinematige-ffr-meting-versus-conventionele-angiografie/","title":"RIPCORD 2: routinematige FFR-meting versus conventionele angiografie","published":"2022-08-30","doi":"10.1161/CIRCULATIONAHA.121.057793","journal":"Circulation","significance":7}]},{"trial":"Re-PERFUSE","count":1,"first_published":"2025-12-01","last_published":"2025-12-01","articles":[{"url":"https://hartvaat.nl/2025/12/01/re-perfuse-relaxinereceptoragonist-en-renale-perfusie-bij-hfref-fase-1b/","title":"Re-PERFUSE: relaxinereceptoragonist en renale perfusie bij HFrEF — fase 1b","published":"2025-12-01","doi":"10.1002/ehf2.15412","journal":"ESC heart failure","significance":6}]},{"trial":"Reduce-MFA DZHK25","count":1,"first_published":"2026-06-28","last_published":"2026-06-28","articles":[{"url":"https://hartvaat.nl/2026/05/05/reduce-mfa-dzhk25-trial-naar-antifibrotische-therapie-tegen-myocardfibrose-na-ta/","title":"Reduce-MFA DZHK25: trial naar antifibrotische therapie tegen myocardfibrose na TAVI — opzet en achtergrond","published":"2026-06-28","doi":"10.1093/eschf/xvag083","journal":"ESC heart failure","significance":5}]},{"trial":"SANTORINI UK","count":1,"first_published":"2026-05-08","last_published":"2026-05-08","articles":[{"url":"https://hartvaat.nl/2026/04/24/santorini-uk-ldl-doel-onbereikt-bij-meerderheid-van-hoogrisicopatienten-na-1-jaa/","title":"SANTORINI UK: LDL-doel onbereikt bij meerderheid van hoogrisicopatiënten na 1 jaar","published":"2026-05-08","doi":"10.1136/bmjopen-2025-114031","journal":"BMJ open","significance":6}]},{"trial":"SCIENCE II","count":1,"first_published":"2024-12-01","last_published":"2024-12-01","articles":[{"url":"https://hartvaat.nl/2024/12/01/science-ii-mesenchymale-stamcellen-bij-niet-ischemisch-hartfalen-negatieve-trial/","title":"SCIENCE II: mesenchymale stamcellen bij niet-ischemisch hartfalen — negatieve trial","published":"2024-12-01","doi":"10.1002/ehf2.14925","journal":"ESC heart failure","significance":6}]},{"trial":"SCOFF","count":1,"first_published":"2024-12-16","last_published":"2024-12-16","articles":[{"url":"https://hartvaat.nl/2024/12/16/scoff-nuchter-versus-niet-nuchter-voor-hartkatheterisatie-rct/","title":"SCOFF: nuchter versus niet-nuchter vóór hartkatheterisatie — RCT","published":"2024-12-16","doi":"10.1093/eurheartj/ehae573","journal":"European heart journal","significance":7}]},{"trial":"SCOT-HEART","count":1,"first_published":"2025-01-25","last_published":"2025-01-25","articles":[{"url":"https://hartvaat.nl/2025/01/25/scot-heart-ct-coronairangiografie-bij-stabiele-thoracale-pijn-tienjaarsresultate/","title":"SCOT-HEART: CT-coronairangiografie bij stabiele thoracale pijn — tienjaarsresultaten","published":"2025-01-25","doi":"10.1016/S0140-6736(24)02679-5","journal":"Lancet (London, England)","significance":8}]},{"trial":"SELECT","count":1,"first_published":"2023-12-14","last_published":"2023-12-14","articles":[{"url":"https://hartvaat.nl/2023/12/14/select-semaglutide-vermindert-cv-events-bij-obesitas-zonder-diabetes-nejm/","title":"SELECT: semaglutide vermindert CV-events bij obesitas zonder diabetes — NEJM","published":"2023-12-14","doi":"10.1056/NEJMoa2307563","journal":"The New England journal of medicine","significance":10}]},{"trial":"SINGLE-AF","count":1,"first_published":"2026-08-28","last_published":"2026-08-28","articles":[{"url":"https://hartvaat.nl/2026/08/28/single-af-doac-beschermt-patienten-met-atriumfibrilleren-en-een-risicofactor-zon/","title":"SINGLE-AF: DOAC beschermt patiënten met atriumfibrilleren en één risicofactor, zonder meer ernstige bloedingen","published":"2026-08-28","doi":"10.1056/NEJMoa2607978","journal":"New England Journal of Medicine","significance":8}]},{"trial":"SMART","count":1,"first_published":"2024-06-06","last_published":"2024-06-06","articles":[{"url":"https://hartvaat.nl/2024/06/06/smart-zelf-expanderend-versus-ballonexpandeerbaar-tavr-bij-kleine-annulus-nejm/","title":"SMART: zelf-expanderend versus ballonexpandeerbaar TAVR bij kleine annulus — NEJM","published":"2024-06-06","doi":"10.1056/NEJMoa2312573","journal":"The New England journal of medicine","significance":8}]},{"trial":"SORT OUT XI","count":1,"first_published":"2025-07-15","last_published":"2025-07-15","articles":[{"url":"https://hartvaat.nl/2025/07/15/sort-out-xi-biomatrix-versus-duale-therapie-sirolimus-eluting-stent-bij-pci/","title":"SORT OUT XI: biomatrix versus duale-therapie sirolimus-eluting stent bij PCI","published":"2025-07-15","doi":"10.1016/j.jacc.2025.05.012","journal":"Journal of the American College of Cardiology","significance":6}]},{"trial":"SPACE","count":1,"first_published":"2024-04-01","last_published":"2024-04-01","articles":[{"url":"https://hartvaat.nl/2024/04/01/space-raas-remmers-stoppen-versus-continueren-voor-niet-cardiale-chirurgie/","title":"SPACE: RAAS-remmers stoppen versus continueren voor niet-cardiale chirurgie","published":"2024-04-01","doi":"10.1093/eurheartj/ehad716","journal":"European heart journal","significance":7}]},{"trial":"SPYRAL HTN-ON MED","count":1,"first_published":"2024-05-01","last_published":"2024-05-01","articles":[{"url":"https://hartvaat.nl/2024/05/01/spyral-htn-on-med-renale-denervatie-en-medicatiewijzigingen/","title":"SPYRAL HTN-ON MED: renale denervatie en medicatiewijzigingen","published":"2024-05-01","doi":"10.1161/HYPERTENSIONAHA.123.22251","journal":"Hypertension (Dallas, Tex. : 1979)","significance":6}]},{"trial":"STAMI","count":1,"first_published":"2026-07-10","last_published":"2026-07-10","articles":[{"url":"https://hartvaat.nl/2026/05/04/stami-linkerventrikel-trombus-komt-na-voorwand-stemi-voor-8-bij-takotsubo-nooit-/","title":"STAMI: linkerventrikel-trombus komt na voorwand-STEMI voor (8%), bij Takotsubo nooit — ondanks slechtere LVEF","published":"2026-07-10","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004154?rss=1","journal":"Open Heart","significance":6}]},{"trial":"STELLAR","count":1,"first_published":"2023-04-20","last_published":"2023-04-20","articles":[{"url":"https://hartvaat.nl/2023/04/20/stellar-sotatercept-bij-pulmonale-arteriele-hypertensie-nejm-fase-3/","title":"STELLAR: sotatercept bij pulmonale arteriële hypertensie — NEJM fase 3","published":"2023-04-20","doi":"10.1056/NEJMoa2213558","journal":"The New England journal of medicine","significance":10}]},{"trial":"STEP","count":1,"first_published":"2023-12-01","last_published":"2023-12-01","articles":[{"url":"https://hartvaat.nl/2023/12/01/step-trial-diastolische-bloeddruk-beinvloedt-effect-van-intensieve-behandeling/","title":"STEP-trial: diastolische bloeddruk beïnvloedt effect van intensieve behandeling","published":"2023-12-01","doi":"10.1161/HYPERTENSIONAHA.123.21892","journal":"Hypertension (Dallas, Tex. : 1979)","significance":6}]},{"trial":"STEP-HFpEF-DM","count":1,"first_published":"2024-04-18","last_published":"2024-04-18","articles":[{"url":"https://hartvaat.nl/2024/04/18/step-hfpef-dm-semaglutide-bij-hfpef-met-obesitas-en-type-2-diabetes-nejm/","title":"STEP-HFpEF-DM: semaglutide bij HFpEF met obesitas en type 2 diabetes — NEJM","published":"2024-04-18","doi":"10.1056/NEJMoa2313917","journal":"The New England journal of medicine","significance":10}]},{"trial":"STOP","count":1,"first_published":"2024-08-27","last_published":"2024-08-27","articles":[{"url":"https://hartvaat.nl/2024/08/27/stop-semaglutide-vermindert-epicardiaal-vetweefsel-bij-type-2-diabetes/","title":"STOP: semaglutide vermindert epicardiaal vetweefsel bij type 2 diabetes","published":"2024-08-27","doi":"10.1016/j.jacc.2024.05.065","journal":"Journal of the American College of Cardiology","significance":6}]},{"trial":"STOP-CA","count":1,"first_published":"2023-08-08","last_published":"2023-08-08","articles":[{"url":"https://hartvaat.nl/2023/08/08/stop-ca-atorvastatine-beschermt-tegen-antracycline-cardiotoxiciteit/","title":"STOP-CA: atorvastatine beschermt tegen antracycline-cardiotoxiciteit","published":"2023-08-08","doi":"10.1001/jama.2023.11887","journal":"JAMA","significance":8}]},{"trial":"STOP-CAD","count":1,"first_published":"2026-06-10","last_published":"2026-06-10","articles":[{"url":"https://hartvaat.nl/2026/05/19/stop-cad-1-op-6-cervicale-arteriedissecties-wordt-aanvankelijk-verkeerd-gediagno/","title":"STOP-CAD: 1 op 6 cervicale arteriedissecties wordt aanvankelijk verkeerd gediagnosticeerd","published":"2026-06-10","doi":"10.1161/JAHA.125.046408","journal":"Journal of the American Heart Association","significance":6}]},{"trial":"STOPDAPT-3","count":1,"first_published":"2024-02-20","last_published":"2024-02-20","articles":[{"url":"https://hartvaat.nl/2024/02/20/stopdapt-3-aspirinevrij-versus-standaard-dapt-na-coronaire-stenting/","title":"STOPDAPT-3: aspirinevrij versus standaard DAPT na coronaire stenting","published":"2024-02-20","doi":"10.1161/CIRCULATIONAHA.123.066720","journal":"Circulation","significance":8}]},{"trial":"STOPSTORM","count":1,"first_published":"2026-05-01","last_published":"2026-05-01","articles":[{"url":"https://hartvaat.nl/2026/04/20/stopstorm-stereotactische-bestraling-reduceert-refractaire-vt-met-80/","title":"STOPSTORM: stereotactische bestraling reduceert refractaire VT met 80%","published":"2026-05-01","doi":"10.1093/eurheartj/ehag338","journal":"European heart journal","significance":9}]},{"trial":"STREAM-2","count":1,"first_published":"2023-08-29","last_published":"2023-08-29","articles":[{"url":"https://hartvaat.nl/2023/08/29/stream-2-halve-dosis-tenecteplase-bij-ouderen-met-stemi/","title":"STREAM-2: halve-dosis tenecteplase bij ouderen met STEMI","published":"2023-08-29","doi":"10.1161/CIRCULATIONAHA.123.064521","journal":"Circulation","significance":7}]},{"trial":"STRIP","count":1,"first_published":"2024-09-01","last_published":"2024-09-01","articles":[{"url":"https://hartvaat.nl/2024/09/01/strip-20-jaarsresultaten-van-dieetinterventie-vanaf-de-zuigelingenleeftijd/","title":"STRIP: 20-jaarsresultaten van dieetinterventie vanaf de zuigelingenleeftijd","published":"2024-09-01","doi":"10.1093/eurheartj/ehae423","journal":"European heart journal","significance":7}]},{"trial":"STRIVE","count":1,"first_published":"2026-03-16","last_published":"2026-03-16","articles":[{"url":"https://hartvaat.nl/2025/01/01/strive-trial-neutraal-resultaat-herformuleert-uitdaging-microvasculaire-obstruct/","title":"STRIVE-trial: neutraal resultaat herformuleert uitdaging microvasculaire obstructie","published":"2026-03-16","doi":"https://www.sciencedirect.com/science/article/pii/S0735109726001257?dgcid=rss_sd_all","journal":"JACC","significance":7}]},{"trial":"STROKESTOP","count":1,"first_published":"2023-01-14","last_published":"2023-01-14","articles":[{"url":"https://hartvaat.nl/2023/01/14/strokestop-af-screening-is-kosteneffectief-bij-75-76-jarigen/","title":"STROKESTOP: AF-screening is kosteneffectief bij 75-76-jarigen","published":"2023-01-14","doi":"10.1093/eurheartj/ehac547","journal":"European heart journal","significance":8}]},{"trial":"STYLE-AF","count":1,"first_published":"2024-05-02","last_published":"2024-05-02","articles":[{"url":"https://hartvaat.nl/2024/05/02/style-af-veneuze-closure-device-versus-figuur-van-acht-hechting-na-af-ablatie/","title":"STYLE-AF: veneuze closure device versus figuur-van-acht hechting na AF-ablatie","published":"2024-05-02","doi":"10.1093/europace/euae105","journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","significance":5}]},{"trial":"SUBCUT HF II","count":1,"first_published":"2026-05-11","last_published":"2026-05-11","articles":[{"url":"https://hartvaat.nl/2026/05/09/subcut-hf-ii-subcutane-furosemide-thuis-verlaagt-opnameduur-met-5-5-dagen-na-har/","title":"SUBCUT HF II: subcutane furosemide thuis verlaagt opnameduur met 5,5 dagen na hartfalenopname","published":"2026-05-11","doi":"https://www.prnewswire.com/news-releases/results-of-the-randomized-controlled-trial-of-at-home-subcutaneous-diuretic-therapy-for-heart-failure-associated-edema-to-be-presented-at-heart-failure-2026-302760746.html","journal":"Heart Failure 2026 (Late-Breaking Science)","significance":8}]},{"trial":"SWEDEHEART","count":1,"first_published":"2026-07-05","last_published":"2026-07-05","articles":[{"url":"https://hartvaat.nl/2026/05/21/swedeheart-na-een-eerste-hartinfarct-is-fysieke-fitheid-bij-start-cardiale-reval/","title":"SWEDEHEART: na een eerste hartinfarct is fysieke fitheid bij start cardiale revalidatie ver onder de norm","published":"2026-07-05","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004046?rss=1","journal":"Open Heart","significance":6}]},{"trial":"SWISS-APERO","count":1,"first_published":"2024-02-06","last_published":"2024-02-06","articles":[{"url":"https://hartvaat.nl/2024/02/06/swiss-apero-amulet-versus-watchman-na-1-jaar-voor-laa-sluiting/","title":"SWISS-APERO: Amulet versus Watchman na 1 jaar voor LAA-sluiting","published":"2024-02-06","doi":"10.1161/CIRCULATIONAHA.123.067599","journal":"Circulation","significance":6}]},{"trial":"SYMPLICITY HTN-3","count":1,"first_published":"2022-10-22","last_published":"2022-10-22","articles":[{"url":"https://hartvaat.nl/2022/10/22/symplicity-htn-3-langetermijn-follow-up-renale-denervatie-bij-resistente-hyperte/","title":"SYMPLICITY HTN-3: langetermijn follow-up renale denervatie bij resistente hypertensie","published":"2022-10-22","doi":"10.1016/S0140-6736(22)01787-1","journal":"Lancet (London, England)","significance":7}]},{"trial":"T-PASS","count":1,"first_published":"2024-02-20","last_published":"2024-02-20","articles":[{"url":"https://hartvaat.nl/2024/02/20/t-pass-ticagrelor-monotherapie-binnen-1-maand-na-stenting-bij-acs/","title":"T-PASS: ticagrelor monotherapie binnen 1 maand na stenting bij ACS","published":"2024-02-20","doi":"10.1161/CIRCULATIONAHA.123.066943","journal":"Circulation","significance":8}]},{"trial":"TACT-2","count":1,"first_published":"2024-09-10","last_published":"2024-09-10","articles":[{"url":"https://hartvaat.nl/2024/09/10/tact-2-chelatietherapie-na-mi-bij-diabetes-negatieve-trial/","title":"TACT-2: chelatietherapie na MI bij diabetes — negatieve trial","published":"2024-09-10","doi":"10.1001/jama.2024.11463","journal":"JAMA","significance":7}]},{"trial":"TALOS-AMI","count":1,"first_published":"2024-02-01","last_published":"2024-02-01","articles":[{"url":"https://hartvaat.nl/2024/02/01/talos-ami-dapt-de-escalatie-veilig-bij-mi-met-hoog-ischemisch-risico/","title":"TALOS-AMI: DAPT de-escalatie veilig bij MI met hoog ischemisch risico","published":"2024-02-01","doi":"10.1001/jamacardio.2023.4587","journal":"JAMA cardiology","significance":7}]},{"trial":"TANDEM","count":1,"first_published":"2025-05-17","last_published":"2025-05-17","articles":[{"url":"https://hartvaat.nl/2025/05/17/tandem-obicetrapib-plus-ezetimibe-voor-ldl-verlaging-lancet-fase-3/","title":"TANDEM: obicetrapib plus ezetimibe voor LDL-verlaging — Lancet fase 3","published":"2025-05-17","doi":"10.1016/S0140-6736(25)00721-4","journal":"Lancet (London, England)","significance":9}]},{"trial":"TARGET BP I","count":1,"first_published":"2024-06-11","last_published":"2024-06-11","articles":[{"url":"https://hartvaat.nl/2024/06/11/target-bp-i-alcohol-gemedieerde-renale-denervatie-bij-hypertensie/","title":"TARGET BP I: alcohol-gemedieerde renale denervatie bij hypertensie","published":"2024-06-11","doi":"10.1161/CIRCULATIONAHA.124.069291","journal":"Circulation","significance":7}]},{"trial":"TELEREH-HF","count":1,"first_published":"2021-04-01","last_published":"2021-04-01","articles":[{"url":"https://hartvaat.nl/2021/04/01/telereh-hf-etiologie-subanalyse-van-telerevalidatie-bij-hartfalen/","title":"TELEREH-HF: etiologie-subanalyse van telerevalidatie bij hartfalen","published":"2021-04-01","doi":"10.1002/ehf2.13189","journal":"ESC heart failure","significance":5}]},{"trial":"TELESAT PRIOR-HF","count":1,"first_published":"2026-05-10","last_published":"2026-05-10","articles":[{"url":"https://hartvaat.nl/2026/05/09/telesat-prior-hf-telemonitoring-na-hartfalenopname-verbonden-met-46-lagere-morta/","title":"TELESAT PRIOR-HF: telemonitoring na hartfalenopname verbonden met 46% lagere mortaliteit","published":"2026-05-10","doi":"10.1093/ejhf/xuag146","journal":"European Journal of Heart Failure","significance":7}]},{"trial":"TIGHT K","count":1,"first_published":"2024-09-24","last_published":"2024-09-24","articles":[{"url":"https://hartvaat.nl/2024/09/24/tight-k-kaliumsuppletie-voorkomt-af-na-hartchirurgie-rct/","title":"TIGHT K: kaliumsuppletie voorkomt AF na hartchirurgie — RCT","published":"2024-09-24","doi":"10.1001/jama.2024.17888","journal":"JAMA","significance":7}]},{"trial":"TIME","count":1,"first_published":"2022-10-22","last_published":"2022-10-22","articles":[{"url":"https://hartvaat.nl/2022/10/22/time-avonddosering-antihypertensiva-biedt-geen-voordeel-boven-ochtenddosering/","title":"TIME: avonddosering antihypertensiva biedt geen voordeel boven ochtenddosering","published":"2022-10-22","doi":"10.1016/S0140-6736(22)01786-X","journal":"Lancet (London, England)","significance":9}]},{"trial":"TIMING","count":1,"first_published":"2022-10-04","last_published":"2022-10-04","articles":[{"url":"https://hartvaat.nl/2022/10/04/timing-vroege-versus-late-noac-start-na-ischemisch-cva-bij-af/","title":"TIMING: vroege versus late NOAC-start na ischemisch CVA bij AF","published":"2022-10-04","doi":"10.1161/CIRCULATIONAHA.122.060666","journal":"Circulation","significance":8}]},{"trial":"TOP","count":1,"first_published":"2025-12-23","last_published":"2025-12-23","articles":[{"url":"https://hartvaat.nl/2025/12/23/top-liberaal-versus-restrictief-transfusiebeleid-bij-hoogrisico-hartchirurgie/","title":"TOP: liberaal versus restrictief transfusiebeleid bij hoogrisico hartchirurgie","published":"2025-12-23","doi":"10.1001/jama.2025.20841","journal":"JAMA","significance":7}]},{"trial":"TOUCH","count":1,"first_published":"2025-07-01","last_published":"2025-07-01","articles":[{"url":"https://hartvaat.nl/2025/07/01/touch-seh-educatie-en-mhealth-voor-hypertensie-gerandomiseerde-trial/","title":"TOUCH: SEH-educatie en mHealth voor hypertensie — gerandomiseerde trial","published":"2025-07-01","doi":"10.1001/jamacardio.2025.0675","journal":"JAMA cardiology","significance":6}]},{"trial":"TRAVERSE","count":1,"first_published":"2023-07-13","last_published":"2023-07-13","articles":[{"url":"https://hartvaat.nl/2023/07/13/traverse-testosteronsubstitutie-cardiovasculair-veilig-bij-hypogonadisme/","title":"TRAVERSE: testosteronsubstitutie cardiovasculair veilig bij hypogonadisme","published":"2023-07-13","doi":"10.1056/NEJMoa2215025","journal":"The New England journal of medicine","significance":9}]},{"trial":"TRICORDER","count":1,"first_published":"2026-02-14","last_published":"2026-02-14","articles":[{"url":"https://hartvaat.nl/2026/02/14/tricorder-ai-stethoscoop-voor-triple-cv-ziektedetectie/","title":"TRICORDER: AI-stethoscoop voor triple CV-ziektedetectie","published":"2026-02-14","doi":"10.1016/S0140-6736(25)02156-7","journal":"Lancet (London, England)","significance":7}]},{"trial":"TRILUMINATE","count":1,"first_published":"2023-05-18","last_published":"2023-05-18","articles":[{"url":"https://hartvaat.nl/2023/05/18/triluminate-transcatheter-tricuspidaliskleprepair-bij-ernstige-tr-nejm/","title":"TRILUMINATE: transcatheter tricuspidaliskleprepair bij ernstige TR — NEJM","published":"2023-05-18","doi":"10.1056/NEJMoa2300525","journal":"The New England journal of medicine","significance":9}]},{"trial":"ULYSSES","count":1,"first_published":"2026-07-14","last_published":"2026-07-14","articles":[{"url":"https://hartvaat.nl/2026/04/14/ulysses-echogeleide-venapunctie-halveert-toegangscomplicaties-bij-af-ablatie/","title":"ULYSSES: echogeleide venapunctie halveert toegangscomplicaties bij AF-ablatie","published":"2026-07-14","doi":"10.1093/eurheartj/ehag291","journal":"European heart journal","significance":7}]},{"trial":"VALUE","count":1,"first_published":"2024-07-01","last_published":"2024-07-01","articles":[{"url":"https://hartvaat.nl/2024/07/01/value-trial-cv-uitkomsten-bij-hypertensie-met-perifeer-vaatlijden/","title":"VALUE-trial: CV-uitkomsten bij hypertensie met perifeer vaatlijden","published":"2024-07-01","doi":"10.1161/HYPERTENSIONAHA.124.22832","journal":"Hypertension (Dallas, Tex. : 1979)","significance":5}]},{"trial":"VANISH2","count":1,"first_published":"2025-02-20","last_published":"2025-02-20","articles":[{"url":"https://hartvaat.nl/2025/02/20/vanish2-catheterablatie-versus-antiaritmica-bij-ventriculaire-tachycardie-nejm/","title":"VANISH2: catheterablatie versus antiaritmica bij ventriculaire tachycardie — NEJM","published":"2025-02-20","doi":"10.1056/NEJMoa2409501","journal":"The New England journal of medicine","significance":9}]},{"trial":"VARIPURE","count":1,"first_published":"2026-03-03","last_published":"2026-03-03","articles":[{"url":"https://hartvaat.nl/2026/02/03/varipure-studie-pulsed-field-ablatie-in-de-dagelijkse-af-praktijk/","title":"VARIPURE-studie: pulsed field ablatie in de dagelijkse AF-praktijk","published":"2026-03-03","doi":"10.1093/europace/euag025","journal":"Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology","significance":7}]},{"trial":"VERISEC","count":1,"first_published":"2026-05-15","last_published":"2026-05-15","articles":[{"url":"https://hartvaat.nl/2026/05/13/verisec-vericiguat-in-de-praktijk-halveert-hartfalen-decompensaties-bij-hfref-sp/","title":"VERISEC: vericiguat in de praktijk halveert hartfalen-decompensaties bij HFrEF — Spaanse 1-jaars registry van 835 patiënten","published":"2026-05-15","doi":"10.1093/eschf/xvag138","journal":"ESC Heart Failure","significance":8}]},{"trial":"VERVE-102","count":1,"first_published":"2026-05-25","last_published":"2026-05-25","articles":[{"url":"https://hartvaat.nl/2026/05/25/verve-102-eenmalige-base-editing-schakelt-pcsk9-blijvend-uit-fase-1/","title":"VERVE-102: eenmalige base-editing schakelt PCSK9 blijvend uit (fase 1)","published":"2026-05-25","doi":"10.1056/NEJMoa2601283","journal":"The New England journal of medicine","significance":9}]},{"trial":"VICTORION-INCEPTION","count":1,"first_published":"2026-06-12","last_published":"2026-06-12","articles":[{"url":"https://hartvaat.nl/2026/05/19/victorion-inception-vroege-inclisiran-na-acuut-coronair-syndroom-verviervoudigt-/","title":"VICTORION-INCEPTION: vroege inclisiran na acuut coronair syndroom verviervoudigt het halen van LDL-doel","published":"2026-06-12","doi":"10.1161/JAHA.125.043655","journal":"Journal of the American Heart Association","significance":8}]},{"trial":"VICTORION-INITIATE","count":1,"first_published":"2025-07-22","last_published":"2025-07-22","articles":[{"url":"https://hartvaat.nl/2025/07/22/victorion-initiate-inclisiran-monotherapie-bij-patienten-zonder-ascvd/","title":"VICTORION-INITIATE: inclisiran monotherapie bij patiënten zonder ASCVD","published":"2025-07-22","doi":"10.1016/j.jacc.2025.04.049","journal":"Journal of the American College of Cardiology","significance":7}]},{"trial":"VIP-ACS","count":1,"first_published":"2022-11-01","last_published":"2022-11-01","articles":[{"url":"https://hartvaat.nl/2022/11/01/vip-acs-dubbele-dosis-griepvaccinatie-na-acs-verbetert-uitkomsten-niet/","title":"VIP-ACS: dubbele-dosis griepvaccinatie na ACS verbetert uitkomsten niet","published":"2022-11-01","doi":"10.1093/eurheartj/ehac472","journal":"European heart journal","significance":7}]},{"trial":"VISION","count":1,"first_published":"2026-07-15","last_published":"2026-07-15","articles":[{"url":"https://hartvaat.nl/2026/04/08/vision-postoperatief-atriumfibrilleren-na-hartchirurgie-verhoogt-sterfte-na-een-/","title":"VISION: postoperatief atriumfibrilleren na hartchirurgie verhoogt sterfte na een jaar","published":"2026-07-15","doi":"10.1093/eurheartj/ehag236","journal":"European heart journal","significance":7}]},{"trial":"VOYAGER PAD","count":1,"first_published":"2023-12-12","last_published":"2023-12-12","articles":[{"url":"https://hartvaat.nl/2023/12/12/voyager-pad-rivaroxaban-plus-aspirine-na-endovasculaire-revascularisatie-voor-pa/","title":"VOYAGER PAD: rivaroxaban plus aspirine na endovasculaire revascularisatie voor PAD","published":"2023-12-12","doi":"10.1161/CIRCULATIONAHA.122.063806","journal":"Circulation","significance":7}]},{"trial":"WARRIOR","count":1,"first_published":"2026-07-24","last_published":"2026-07-24","articles":[{"url":"https://hartvaat.nl/2026/04/03/warrior-trial-intensieve-medicamenteuze-behandeling-verbetert-de-uitkomsten-niet/","title":"WARRIOR-trial: intensieve medicamenteuze behandeling verbetert de uitkomsten niet bij vrouwen met ANOCA/INOCA","published":"2026-07-24","doi":"http://openheart.bmj.com/cgi/content/short/13/1/e004115?rss=1","journal":"Open Heart","significance":7}]},{"trial":"WATCHFUL","count":1,"first_published":"2024-01-16","last_published":"2024-01-16","articles":[{"url":"https://hartvaat.nl/2024/01/16/watchful-leefstijl-wandelinterventie-bij-hfref/","title":"WATCHFUL: leefstijl-wandelinterventie bij HFrEF","published":"2024-01-16","doi":"10.1161/CIRCULATIONAHA.123.067395","journal":"Circulation","significance":6}]},{"trial":"WISDOM-HMOD","count":1,"first_published":"2026-07-09","last_published":"2026-07-09","articles":[{"url":"https://hartvaat.nl/2026/05/11/wisdom-hmod-nachtelijke-pols-bloeddrukmeting-voorspelt-onafhankelijk-linkerventr/","title":"WISDOM-HMOD: nachtelijke pols-bloeddrukmeting voorspelt onafhankelijk linkerventrikelhypertrofie","published":"2026-07-09","doi":"https://www.ahajournals.org/doi/abs/10.1161/HYPERTENSIONAHA.125.26510","journal":"Hypertension","significance":7}]},{"trial":"YELLOW-III","count":1,"first_published":"2026-02-24","last_published":"2026-02-24","articles":[{"url":"https://hartvaat.nl/2026/02/24/yellow-iii-intracoronaire-beeldvorming-en-genexpressie-na-maximale-lipideverlagi/","title":"YELLOW-III: intracoronaire beeldvorming en genexpressie na maximale lipideverlaging met evolocumab","published":"2026-02-24","doi":"10.1016/j.jcmg.2025.12.013","journal":"JACC. Cardiovascular imaging","significance":7}]},{"trial":"YOLT-101","count":1,"first_published":"2026-03-03","last_published":"2026-03-03","articles":[{"url":"https://hartvaat.nl/2026/03/03/yolt-101-base-editing-schakelt-pcsk9-uit-bij-heterozygote-fh-fase-1/","title":"YOLT-101: base-editing schakelt PCSK9 uit bij heterozygote FH (fase 1)","published":"2026-03-03","doi":"10.1038/s41591-026-04254-4","journal":"Nature medicine","significance":8}]},{"trial":"ZENITH-CKD","count":1,"first_published":"2023-11-25","last_published":"2023-11-25","articles":[{"url":"https://hartvaat.nl/2023/11/25/zenith-ckd-zibotentan-plus-dapagliflozine-bij-ckd-lancet/","title":"ZENITH-CKD: zibotentan plus dapagliflozine bij CKD — Lancet","published":"2023-11-25","doi":"10.1016/S0140-6736(23)02230-4","journal":"Lancet (London, England)","significance":8}]},{"trial":"aMAZE","count":1,"first_published":"2024-04-02","last_published":"2024-04-02","articles":[{"url":"https://hartvaat.nl/2024/04/02/amaze-pvi-met-of-zonder-laa-ligatie-bij-af-jama-rct/","title":"aMAZE: PVI met of zonder LAA-ligatie bij AF — JAMA RCT","published":"2024-04-02","doi":"10.1001/jama.2024.3026","journal":"JAMA","significance":7}]}]}